 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210739] OF DEFINITIONS  ..................................................................................................................... 9  
PROTOCOL APPROVAL PAGE  .................................................................................................... 10  
STATEMENT OF COMPLIA NCE  .................................................................................................. 11  
PROTOCOL SUMMARY ................................................................................................................. 12  
SCHEMATIC OF STUDY DESIGN ................................................................................................ 15  
1 KEY ROLES  ........................................................................................................................... 15  
1.1 AUTHORIZED REPRESENTATIVE (SIGNATORY) / RESPONSIBLE PARTY  ........ 15 
1.2 STUDY ORGANIZATION .................................................................................................... 15 
2 INTRODUCTION .................................................................................................................. 15  
2.1 BACKGROUND INFORMATI ON ...................................................................................... 15 
2.2 RATIONALE  .......................................................................................................................... 17 
2.3 POTENTIAL RISKS AND BENEFITS  ............................................................................... 19  
2.3.1  KNOWN POTENTIAL RISK S ................................................................................................ 19 
2.3.2  KNOWN POTENTIAL BENE FITS  ......................................................................................... 20 
3 OBJECTIVES AND PURPO SE ........................................................................................... 20  
4 STUDY DESIGN AND ENDPOINTS  .................................................................................. 20  
4.1 DESCRIPTION OF THE STUDY DESIGN ........................................................................ 20 
4.2 STUDY ENDPOINTS  ............................................................................................................ 21 
4.2.1  PRIMARY ENDPOINT ............................................................................................................ 21 
4.2.2  SECONDARY ENDPOINTS  ................................................................................................... 21 
4.2.3  EXPLORATORY ENDPOINTS  .............................................................................................. 22 
5 STUDY ENROLLMENT AND WITHDRAWAL  .............................................................. 22  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210740] STORAGE AND STABILITY .............................................................................. 26 
6.1.4  PREPARATION  ....................................................................................................................... 27 
6.1.5  DOSING AND ADMINISTR ATION ...................................................................................... 27 
6.1.6  ROUTE OF ADMINISTRAT ION ............................................................................................ 27 
6.1.7  DOSING SCHEDULE  .............................................................................................................. 27 
6.1.8  DURATI ON OF THERAPY  .................................................................................................... 28 
6.2 STUDY AGENT ACCOUNTABILITY ................................................................................ 28 
7 STUDY PROCEDURES AND SCHEDULE  ....................................................................... 28  
7.1 STUDY PROCEDURES/EVALUATIONS  .......................................................................... 28 
7.1.1  STUDY SPECIFIC PROCE DURES  ........................................................................................ 28 
7.2 LABORATORY PROCEDURES/EVALUATIONS  ........................................................... 37 
7.2.1  CLINICAL LABORATORY EVALUATIONS  ....................................................................... 37 
7.2.2  OTHER TESTS OR PROCE DURES  ....................................................................................... 37 
7.2.3  SPECIMEN PREPARATION , HANDLING, STORAGE,  AND SHIPPI[INVESTIGATOR_1645]  .......................... 38 
7.3 STUDY SCHEDULE  .............................................................................................................. 38 
7.3.1  SCREENING  ............................................................................................................................ 38 
7.3.2  RANDOMIZATION  ................................................................................................................. 39 
7.3.3  BASELINE  ............................................................................................................................... 39 
7.3.4  TREATMENT  .......................................................................................................................... 40 
7.3.5  FOLLOW -UP............................................................................................................................ 41 
7.3.6  FINAL STUDY VISIT  ............................................................................................................. 42 
7.3.7  EARLY TERMINATION  ......................................................................................................... 43 
7.3.8  SCHE DULE OF EVENTS TABLE  .......................................................................................... 43 
7.4 CONCOMITANT MEDICATIONS  ..................................................................................... 43 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  ...................... 43 
8 ASSESSMENT OF SAFETY  ................................................................................................ 43  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 4 of 111
  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  .............................................................. 43 
8.1.1  DEFINITION OF ADVERS E EVENTS (AE) ......................................................................... 43 
8.1.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SAE) ...................................................... 45 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ................................................................ 46 
8.2.1  SEVERITY OF EVENT  ........................................................................................................... 46 
8.2.2  RELATIONSHIP TO STUD Y AGENT  ................................................................................... 46 
8.2.3  EXPECTEDNESS  .................................................................................................................... 46 
8.3 TIME PERIOD/FREQUENC Y FOR EVENT ASSESSME NT/FOLLOW -UP ................ [ADDRESS_210741]  ..................................................................... 49 
8.4.4  REPORTING OF PREGNAN CY ............................................................................................. 50 
8.5 STUDY HALTING RULES  ................................................................................................... 50 
8.6 SAFETY OVERSIGHT  ......................................................................................................... 51 
9 CLINICAL MONITORING  ................................................................................................. 51  
10 STATISTICAL CONSIDERATIONS  .................................................................................. 52  
10.1  STATISTICAL DESIGN MODEL AND ANALYTICAL PLANS  .................................... 52 
10.2  STATISTICAL HYPOTHESES  ........................................................................................... 52 
10.3  ANALYSIS DATASETS  ........................................................................................................ 52 
10.4  DESCRIPTION OF STATI STICAL METHODS  ............................................................... 53 
10.4.1  GENERAL APPROACH  .......................................................................................................... 53 
10.4.2  ANALYSIS OF THE PRIMARY ENDPOINT  ........................................................................ 53 
10.4.3  ANALYSIS OF THE SECONDARY EFFICACY ENDPOINTS  ............................................ 54 
10.4.4  ANALYSIS OF THE SECONDARY SAFETY ENDPOINTS  ................................................ 54 
10.4.5  ADHERENCE AND RETENTION ANALYSES  .................................................................... 54 
10.4.6  BASELINE DESCRIPTIVE STATISTICS  .............................................................................. 54 
10.4.7  PLANNED INTERIM ANAL YSES  ......................................................................................... 54 
10.4.8  ADDITIONAL SUBGROUP ANALYSES  .............................................................................. 55 
10.4.9  MULTIPLE COMPARISON/ MULTIPLICITY  ....................................................................... 55 
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  ....................................................... 55 
10.4.11  EXPLORATORY ANALYSES  .............................................................................................. 55 
10.5  SAMPLE SIZE........................................................................................................................ 55 
10.6  MEASURES TO MINIMIZE  BIAS  ...................................................................................... 56 
10.6.1  ENROLLMENT/RANDOMIZATION/MASKING PROCEDURES  ...................................... 56 
10.6.2  EVALUATION OF SUCCESS OF BLINDING  ...................................................................... 57 
10.6.3  BREAKING THE STUDY B LIND/SUBJECT CODE  ............................................................ 57 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ............ 57  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 5 of 111
  
 
12 ETHICS/PROTECTION OF  HUMAN SUBJECTS ........................................................... [ADDRESS_210742]/ ETHICS COMMI TTEE ..................................... [ADDRESS_210743] INFORMATION  ..................................................... 90 
18 REVISION HISTORY ........................................................................................................... 91  
18.1  SUMMARY OF CHANGES  .................................................................................................. 91 
  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210744] OF ABBREVIATIONS 
α-Syn Alpha -synuclein  
ACE  Angiotensin converting enzyme  
AD Alzheimer’s disease  
AE Adverse event 
AESI  Adverse event of special interest  
AIC Ambulatory infusion center  
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
ANSM       Agence Nationale de Sécurité du Médicament et des Produits de Santé  
ApoE  Apolipoprotein E  
APTT  Activated partial thromboplastin time  
ASL MRI  Arterial -spin labeling magnetic resonance imaging  
AST  Aspartate transaminase  
BNP  Brain natriuretic peptide  
BP Blood pressure  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
CDR -CCB  Cognitive Drug Research Computerized Cognition Battery  
CFR  Code of Federal Regulations  
CHMP  Committee for Medicinal Products for Human Use  
CISI -PD Clinical Impression of Severity Index – Parkinson’s Disease  
CJD Creutzfeldt -Jakob disease  
CK Creatinine kinase  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Clinical Monitoring Plan  
CRA  Clinical research associate  
CRF  Case Report Form  
CRO  Contract Research Organization  
DBP  Diastolic blood pressure  
DBS  Deep brain stimulation  
dCDT  Digital clock drawing test  
D-KEFS  Delis -Kaplan Executive Function System   
DNA  Deoxyribonucleic acid  
DSMB  Drug Safety Monitoring Board  
ECG  Electrocardiogram  
eGFR  Estimated glomerular filtration rate 
ENT  Ear, nose, throat  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GDS -15 Geriatric Depression Scale -15 
GGT  Gamma -glutamyl transpeptidase  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210745]  
HIV Human immunodeficiency virus  
HIV Ab  Human immunodeficiency virus antibody  
HR Heart rate  
ICH International Conference on Harmonization  
ICH E6 R2  International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use Guidance for Industry, Good Clinical Practice: 
Consolidated Guidance, Revision [ADDRESS_210746]  Modification in diet in renal disease  
MDS -PD Movement Disorder Society’s Clinical Diagnostic Criteria for Parkinson’s 
Disease  
MDS -UPDRS  Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale  
MedDRA  Medical Dictionary for Regulatory Activities  
MHIS  Modified Hachinski Ischemic Scale  
MoCA  Montreal Cognitive Assessment  
MRI  Magnetic resonance imaging  
NODscid  Non-obese diabetic severe combined immunodeficiency  
NSG  NODscid gamma  
PD Parkinson’s disease  
PDD  Parkinson’s disease dementia  
PD-MCI  Parkinson’s disease with mild cognitive impairment  
PDQ -39 Parkinson’s Disease  Quality of Life Questionnaire -39 
PT Preferred Term  
PT/INR  Prothrombin time/international normalized ratio  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210747] operating procedure  
S-STS Sheehan -Suicidality Tracking Scale  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
TEAE  Treatment emergent adverse event  
tf-fMRI  Task -free functional magnetic resonance imaging  
TGA  Therapeutic Goods Administration  
TSH  Thyroid -stimulating hormone  
UPCR  Urine protein -to-creatinine ratio 
US [LOCATION_002]  
vCJD  Variant Creutzfeldt -Jakob disease  
WBC  White blood cell  
WOCBP  Women of childbearing potential  
 
  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210748] OF DEFINITIONS  
Infusion Nurse  The unblinded study personnel,  qualified by [CONTACT_3903], responsible 
for administering the study agent/placebo.  The Infusion Nurse ensures that the study agent (GRF6021/placebo) is allocated appropriately, administered at the 
correct infusion rate, and appropriate blinding techniques are used to prevent 
inadvertent unblinding of study staff and study subjects.   
Infusion Period  The period during which  GRF6021 /placebo  is infused  (estimated to be 
approximately ). 
Outcomes Assessor  The blinded study personn el qualified by [CONTACT_179104]6021 /placebo  
and collecting and/or managing adverse events (AEs) that occur before, during, 
and after the Infusion Period.  

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 11 of 111
  
 
STATEMENT OF COMPLIANCE 
 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled Study to Assess the Safety 
and Tolerability of GRF6021 Infusions in Subjects with Parkinson’s Disease 
and Cognitive Impairment  
Protocol Number:  ALK60 21-201  
Version/Date : V5.0_23SEP2019  
 
By [CONTACT_27616], I: 
• Confirm that my staff and I have carefully read and understand this protocol or protocol amendment 
and are thoroughly familiar with the appropriate use of the investigational agent  described herein. 
• Agree to comply with the conduct and terms of the study specified herein and with any other study 
conduct procedures provided by [CONTACT_1034], Alkahest, Inc., or their designee 
• Agree to assume responsibility for the proper conduct of the study at this site, including complying 
with current relevant versions of the [LOCATION_002] ( US) Food and Drug Administration (FDA) 
regulations, the International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) Good Clinical Practice ( GCP ) guidelines, the Declaration of 
Helsinki, and all applicable rules, regulations, and federal, state, and local laws relating to the conduct of clinical studies and the protection of human subjects.  
• Agree not to implement deviations from or changes to the protocol or protocol amendments without 
agreement from the Sponsor and prior submission to and written approval (where required) from the 
Institutional Review Board (IRB) or Independent Ethics Committee (IEC), except when necessary to eliminate an immediate hazard to the subjects, or for administrative aspects of the study (where permitted by [CONTACT_72016]).  
• Agree to onsite monitoring of all source documents by [CONTACT_124546], Inc. or designee and to onsite inspection of source documents by [CONTACT_4708], including but not limited to the FDA, local governing regulatory bodies, and IRB/IEC inspectors. 
 
 
 
   
Investigator's Signature   [CONTACT_179143]6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 12 of 111  
 
PROTOCOL SUMMARY 
  
Title:  A Randomized, Double -Blind, Placebo -Controlled Study to Assess the 
Safety and Tolerability of GRF6021 Infusions in Subjects with Parkinson’s 
Disease and Cognitive Impairment  
 
Précis:  This is a randomized, double -blind, placebo -controlled study to assess the 
safety and tolerability of GRF6021, a  human  fraction, 
administered by [CONTACT_33980] (IV) infusion to subjects with Parkinson’s disease (PD) and cognitive impairment.  
 The study consists of approximately 90 subjects who  will be randomized in 
a 2:1 ratio  to active treatment  (approximately 60 subjects ) or placebo 
(approximately 30 subjects ).  Subjects will receive one infusion per day of 
active or placebo treatment  for [ADDRESS_210749] a duration of approximately  with a maximum of .  The infusion of active and placebo agents wil l be 
identical  to maintain blinding.  The following measures will be taken to 
ensure adequate allocation concealment during infusions: blinding of 
subjects, trial partners, study coordinators, physicians, and cognitive /motor  
test administrators to treatmen t allocation ; use of blinded Outcomes 
Assessors and unblinded Infusion Nurses; and measures to block view of 
the infusion setup to avoid unblinding.   
 
All subjects will undergo a screening visit , including a  magnetic resonance 
imaging (MRI) scan , baseline visit, two  treatment periods, follow-up visits, 
and an end-of-study/early-termination visit.  During each  5-day treatment  
period, administration of GRF6021/placebo  can occur in an 
inpatient/hospi[INVESTIGATOR_179085] .  All infusions must be 
performed by [CONTACT_179105].  Safety and tolerability assessments will occur at every visit.  
Neurocognitive and motor assessments will be performed at baseline and at periodic visits following dosing.  Subjects who provide explicit consent to 
undergo a second , optional  MRI scan  will have an additional MRI  scan at 
Visit 16 to assess for changes from screening . 
 
Objectives:  The primary objective of the study is to assess the safety and tolerability of 
an infusion dosing regimen of GRF6021 in subjects with PD and cognitive 
impairment.   As a secondary objective, the study will assess the potential 
effects of GRF60 21 on cognition and motor function  as well as changes 
from baseline in clinical  laboratory parameters, vital  signs, body weight, 
and the Sheehan-Suicidality Tracking Scale (S -STS).  The exploratory 
objectives include  serial compositional analysis of plasma to identify 

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 13 of 111  
 
specific biomarkers associated with cognitive and motor function and/or 
indicators of disease progression, and changes on MRI  (in consenting 
subject s).   
 
Endpoints:  Primary E ndpoint :  
• Incidence of treatment- emergent adverse events (TEAEs ) and 
serious adverse events ( SAEs ) identified by [CONTACT_179106]  (MedDRA ) preferred term (PT) and 
grouped by [CONTACT_7204] (SOC).  
Secondary Efficacy Endpoints:  
• Change from baseline in the Montreal Cognitive Assessment 
(MoCA).  
• Change from baseline in Continuity and Power of Attention, Working Memory, and Epi[INVESTIGATOR_179086] (CDR- CCB).  
• Change from baseline in Delis -Kaplan Executive Function System 
(D-KEFS) V erbal F luency . 
• Change from baseline in the Movement Disorde r Society’s Unified 
Parkinson’s Disease Rating Scale (MDS -UPDRS)  1, 2, 3, and total 
score. 
• Change from baseline in the Schwab and England Activities of 
Daily Living (SE-ADL) Scale.  
• Change from baseline in the Clinical Impression of Severity Index – PD (CIS I-PD).  
• Change from baseline in the PD Quality of Life Questionnaire-39 
(PDQ-39). 
• Change from baseline in the Geriatric Depression Scale-15 (GDS -
15). 
• Change from baseline in the digital clock drawing test ( dCDT).  
 
Secondary Safety Endpoints: 
• Change from baseline in clinical laboratory parameters.  
• Change from baseline in vital sign measurements.  
• Change from baseline in body weight. 
• Change from baseline in the S-STS. 
 
Exploratory Endpoints: 
• Proteomic assessment of plasma for investigation of study- related 
biomarkers . 
• Change from baseline in various MRI a ssessment s (in consenting 
subjects) . 
 
Population:  Approximately 90 subjects between 40 and 8 5 years of age with a diagnosis 
of either PD  with mild cognitive impairment (PD -MCI) or P D with 
dementia ( PDD ).  Assuming a drop -out rate of 25%, enrollment at this level 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 14 of 111  
 
will yield approximately 68 evaluable subjects . 
 
Phase:  2 
 
Number of Sites:  Up to 40 sites in the US and ex-US 
Description  of Study 
Agent:  GRF60 21: A  human  fraction for IV infusion  
 
Description of 
Placebo Control 
Agent:  0.9% sodium chloride injection  (saline)  
 
Study Duration:  
Approximately [ADDRESS_210750]  Duration:  Approximately 7 months   
  

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 17 of 111  
 
These studies complemented  the findings from the initial s tudies conducting by [CONTACT_179107] ( Villeda 2011, 
Villeda 2014) and confirmed that  factors present in human plasma pro tect against brain aging and ameliorate age-
related cognitive and motor impairments in mice, laying the foundation for testing this  fraction in 
humans experiencing cognitive  decline from age- related neurodegenerative diseases.  
 
2.[ADDRESS_210751] demonstrated that both Young Plasma  and GRF6021 confer beneficial  outcomes in cognitive 
decline , motor function , neuro inflammation,  synaptic density, and neurogenesis in mouse models  (ALK-2015-
R002, VIV -2016-R003, VIV-2016-R009, VIV -2016-R014, VIV -2016-R020, VIV-2016-R021, VIV -2016-R024, 
VIV-2017-R025, VIV -2017-R036, VIV -2017-R038, VIV-2018-R069, 2018- CET01 , 2018- CRL03,  2018- QPS01 ).   
 Initial Alkahest nonclinical studies were performed  to test whether the positive effects observed with young 
mouse plasma could be rep licated using Young Plasma.  Treatment of aged NODscid (non- obese diabetic severe 
combined immunodeficiency) mice with Young Plasma (100-150 µl per injection, two injections per week for 3-5 
weeks) resulted in improved cognitive and motor performance in st andard behavioral tests ( ALK-2015-R002).   
These cognitive changes were further supported by [CONTACT_179108].  Together, these results provided support for the hypothesis that young human  plasma infusions may 
have functional clinical  benefits, potentially ameliorating or halting the progression of age -related cognitive 
decline.   
 
Subsequent nonclinical studies at Alkahest were performed to test the  effects of GRF6021 using various dosing 
paradigms in NODscid, NSG (NODscid Gamma) , C57BL/6J , and Line 61 α -Synuclein (α -Syn) transgenic mice.  
Initially, mice were dosed with 150 µL of Young Plasma, GRF6021, or saline (control) via IV infusions 2 times per week for 5 weeks ( VIV-2016-R003).  A subsequent study examined the same dosing regimen for a period of 
[ADDRESS_210752] ion over a 
period of approximately 6 months ( VIV-2016-R014) .  Following these studies, a novel dosing regimen for 
GRF6021 that consisted  of one 150 µL dose every day for 7 consecutive days (referred to as “pulsed dosing”)  was 
assess ed, both alone and compared to other intermittent weekly dosing regimens ( VIV-2016-R009, VIV -2016-
R021, VIV -2016- R024, VIV-2017-R025, 2018- CET -01, 2018- CRL03 , 2018- QPS01 ).  Add i
 tional stud ies 
examined dosing of 150 µL for 5 consecutive days ( VIV-2017-R038) as w ell as subsequent booster dosing for 5 
consecutive days ( VIV-2017-R036) which is the pulsed- dosing regimen chosen for ALK60 21-201.   
 These studies demons trated  that pulse d dosing with GRF6021 led to significant improvements  in cognitive 
performance, motor function, and histological correlates.  Furthermore, t he beneficial effects lasted  up to 3 
months after the end of dosing, suggesting that continuous repeat dosing may not be required ( VIV-2017- R036 , 
VIV-2017-R038).  After pulsed dosing with GRF6021 in old mice , there is a well -defined timecourse of effects 
on the brain.  Within hours of the end of dosing, C- fos expression increases, demonstrating that GRF6021 
administered intravenously results in neuronal activation ( 2018- CET01 ).  Over the  course of a few days to a few 
weeks, there is a reduction in age- related neuroinflammation , and an improvement in age- related deficits in 
cognition and locomotion ( 2018- CET -01, 2018- CRL03 , 2018- QPS01 ).  Lastly, there is an increase in synaptic 
density and hippocampal neurogenesis; the latter lasts for up to 11 weeks after the end of dosing ( VIV-2017-
R038).  Together, these studies indicate that 5 consecutive days of dosing (“pulsed dosing”) of GRF6021  and 
cognitive and other testing for a period of 11 weeks thereafter, followed by a second “booster” dosing period is a 
reasonable study design in human subjects  (VIV-2017-R036).     

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 20 of 111  
 
The capacity of the GRF6021 manufacturing process to inactivate and/or remove viruses was evaluated in viral validation studies designed in accordance with the quality standards established by [CONTACT_179109] (CHMP) and the US FDA.   Studies were performed using 
relevant viruses or models of human viruses that represent a wide range of physicochemic al properties.  
Human immunodeficiency virus  (HIV)  type 1 was used as a relevant bloodborne pathogen, bovine viral 
diarrhea virus was used to model hepatitis C virus (HCV) , and pseudorabies virus was used as a surrogate for 
large, enveloped deoxyribonuclei c acid ( DNA) viruses to model hepatitis B virus  (HBV)  for which there is 
not practicable assay system.  Reovirus type [ADDRESS_210753] 1 log10 
were combined to determine the overall clearance capacities, which demonstrate that the manufacturing 
process for GRF6021 has the capacity to remove and/or inactivate a diverse variety of enveloped and non-
enveloped virus challenges and thereby [CONTACT_179110] a margin of safety from the risk of transmission of infectious viruses.  
 
GRF6021 is contraindicated in patients with severe anemia, congestive h eart failure, or increased blood 
volume ( PI) and these are exclusion criteria in this study.  GRF6021 is depleted of the majority of 
immunogenic proteins  during the manufacturing process, and thus is not expect ed to alter the blood typi[INVESTIGATOR_167027]  
.  ABO antigen typi[INVESTIGATOR_167028].  GRF6 021 is not expected to significantly 
alter the urinalyses of recipi[INVESTIGATOR_840], their bleeding times, coagulation times, prothrombin times, prothrombin consumption, platelet counts, or fibrinogen levels when given in quantities of up to 1000 mL    
 
Based on the cumulative review  (PSUR ), the production steps 
taken to increase the safety margin and avoid virus trans missions, and the multiple safety minimization steps 
implemented in this study,  the benefit -risk balance for GRF6021 as an investigative product in PD-MCI and 
PDD is favorable. 
 
2.3.2 KNOWN POTENTIAL BENEFITS  
 There is no known reported benefit of administering GRF60 21 to patients with PD-MCI or PDD .   
 
3 OBJECTIVES AND PURPOSE 
 
The primary objective of this study is to assess the safety and tolerability of GRF60 21, a  human  
fraction administered by [CONTACT_16228], in subjects with PD and cognitive impairment.  Secondarily, this study aims to assess the effects of GRF60 21 on subjects’ cognitive and motor function.  E xploratory objectives include  blood 
and plasma collection to identify specific biomarkers associated with cognitive and motor changes and/or 
indicators of PD -MCI and PDD  progression.  In addition, MRI of the brain will be conducted  after the second 
treatment  period in consenting subjects to identify potential therapeutic effect s of GRF6021.   
 
4 STUDY DESIGN AND ENDPOINTS 
4.1 DESCRIPTION OF THE STUDY DESIGN  
 
This will be a randomized, double -blind, placebo -controlled study conducted at up to 40 sites in the U S and ex -

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 21 of 111  
 
US.   
 
During the screening p eriod  (Day -35 through Day -8) , subjects will undergo all screening assessments, including 
a screening  MRI  and an echocardiogram, and complete two training sessions on the Continuity and Power of 
Attention, Working Memory, and Epi[INVESTIGATOR_179087]- CCB.   During the Baseline Vi sit (Day -7 
through Day -1) , subjects will complete  cognitive and motor testing .  Subjects will then be randomized in a 2 :1 
ratio to GRF6021 (Group 1)  or placebo (Group 2).   
 
There will be two ( 2) dosing periods.  Each  dosing period (Treatment 1 , starting at Week 1 ; and Treatment 2, 
starting at Week 13)  consists of 5 consecutive days (“pulsed dosing”) of IV infusions of  of either 
GRF60 21 or placebo.  During each  5-day treatment period, the administration of GRF6021/placebo will occur in  
a setting with appro priate medical monitoring by [CONTACT_28788]. The infusions can occur in the 
inpatient/hospi[INVESTIGATOR_179088] . Following a 4-hour 
post- infusion monitoring period, the subject may return home if medically stable based on the investigator’s 
clinical judgement . Should further monitoring be required, subjects may need to remain at and/or be transferred to 
an appropriate facility  for extended outpatient monitoring and/or inpatient observation. 
 
 Safety and tolerability assessments will occur at every visit.  C ognitive and motor testing  will be performed at 
Baseline and at periodic interim visits following dosing.  Cognitive and motor t esting may take up to 
approximately 2.5 hours .  It is pre ferred that the sequence of tests administered should be consistent for all 
subjects.  S ubjects (and /or their trial partners , if applicable) may take breaks between assessments  as needed.  
 In the event of early termination of a subject who has received at least one infusion , the end of study procedures 
will be performed unless the subject has withdrawn consent.  A comprehensive efficacy and safety assessment of all data in toto  will be conducted at the end of the study. 
 
Subjects will also be invited to participate in an additional MRI obtained at Visit [ADDRESS_210754] potential changes in  
brain atrophy, cortical thinning, functional connectivity , and cerebral blood flow  after treatment.  The MRI 
procedure, as well as the poten tial risks and benefits, will be explained to all study participants.  Participation in 
the Visit 16 MRI scan is optional and not required for inclusion in the study.  
 
The overall duration of the study /recruitment period is approximately 24 months from study initiation (i.e., 
following consent of f irst subject ) to study completion (i.e., last subject, last visit).  The subject participation 
period is approximately 7 months from Screening through End of Study, unless prematurely discontinued.  
 
4.2 STUDY ENDPOINTS  
 
4.2.1 PRIMARY ENDPOINT  
 
Primary Endpoint:  
• Incidence of TEAEs and SAEs identified by [CONTACT_179111] S OC.  
 
4.2.[ADDRESS_210755] statistically significant differences in cognitive or motor domains between 

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 22 of 111  
 
the Baseline and End of Study values.  Secondary endpoints will be summarized over the study period from Baseline values using descriptive statistics. 
 
Secondary Efficacy Endpoints:  
• Change from baseline in the MoCA ( Nasreddine 2005 )(Appendix 1). 
• Change from baseline in Co ntinuity and Power of Attention, Working Memory, and Epi[INVESTIGATOR_179089] -CCB ( Wesnes 1977, Wesnes 2000 ). 
• Change from baseline in D- KEFS V erbal F luency  (Delis 2001, Delis 2004, Emre 2004).    
• Change from baseline in the M DS-UPDRS  1, 2, 3, and total score ( Fahn 1987, Movement Disorders 
Task Force 2003 )(Appendix 2).  
• Change from baseline in the SE- ADL Scale  (Schwab 1968)(Appendix 3 ). 
• Change from baseline in the CISI- PD (Martinez-Martin 2006)( Appendix 4).   
• Change from baseline in the PDQ-39 ( Peto 1998 )(Appendix 5).  
• Change from baseline in the GDS-15 ( Yesavage 1983 )(Appendix 6 ). 
• Change from baseline in the dC DT (Müller 2017).  
 Secondary Safety Endpoints: 
• Change from baseline in clinical laboratory parameters.  
• Change from baseline in vital sign measurements.  
• Change from baseline in body weight. 
• Change from baseline in the S- STS ( Sheehan  2014)( Appendix 7). 
 
4.2.3 EXPLORATORY ENDPOINT S 
 
The exploratory endpoints include assessment of changes in composition and distribution of blood- based 
biomarkers and changes in  MRI  assessments (in consenting subjects) .   
 The serial compositional analysis of individual subject’s plasma will be performed to identify specific 
biomarkers associated with cognitive functional changes and/or indicators of disease progression.  DNA will 
be extracted from blood samples to explore epi[INVESTIGATOR_14364].    
In addition, brain imaging (MRI) will be conducted in consenting subjects to identify potential therapeutic 
effect s of GRF6021.  The following changes from baseline may be evaluated:  
• Brain morphometry as measured by [CONTACT_9268].  
• Functional connectivity as measured by [CONTACT_55463]-free functional MRI (tf- fMRI), where available.  
• Cerebral blood flow assessments as measured by [CONTACT_179112] -spin labeling (ASL) MRI, where available.  
 
[ADDRESS_210756] meet the following criteria:  
1. Aged 40-85 years at time of enrollment, inclusive.  
2. Diagnosis of clinically established or clinically probable PD according to M DS-PD criteria  (Postuma 
2015)( Appendix 8 ) with at least 1 year of PD symptoms. 
3. Diagnosis of PD -MCI  (Level I, i.e. i mpairment on a scale of global cognitive abilities validated for 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 23 of 111  
 
use in PD) or probable or possible PDD according to MDS criteria ( Litvan 2012,  Emre 
2007)( Appendix 9 ). 
4. Score on the MoCA of 13-25, inclusive  (Nasreddine 2005 )(Appendix 1 ). 
5. Hoehn and Yahr Stages 1- 4. 
6. If on dopaminergic therapy ( e.g., levodopa, dopamine agonists, monoamine oxidase inhibitors, 
catechol -O-methyl transferase inhibitors, amantadine), must be on stable dosage at least 4 weeks 
prior to baseline. 
7. If on medications for cognition (e.g., rivastigmine, galantamine, donepezil, memantine), must be on stable dosage for at least [ADDRESS_210757] be on stable dosage for 8 weeks prior to baseline. 
10. Renal function as defined by e stimated glomerular filtration rate (e GFR ) ≥ 45 mL/min/1.73 m
2 using 
the Modification of Diet in Renal Disease (MDRD)  study equation and no microalbuminuria. 
11. Systolic ejection fraction of ≥  55% on trans -thoracic echocardiogram.  
12. Modified Hachinski Ischemic Scale (MHIS)  score of 4 or less ( Rosen 1980 ). 
13. Female subjects must not be pregnant or breastfeeding.  Women of childbearing potential (WOCBP)  
must have a negative pregnancy test at screening  (Visit 1) , Visit 3 (prior to study treatment), and 
Visit 11 (prior to study treatment) .  WOCBP  must agree to use highly effective contraception prior 
to study entry ( Clinical Trial Facilitation Group 2014 ).  A woman is considered of childbearing 
potential following menarche and unt il becoming postmenopausal (no menses for at least 2 years 
without an alternative cause).  Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in the study, she should inform her tre ating physician immediately. 
14. Have a dedicated, reliable, and competent trial partner (e.g., caregiver or family member) who has 
frequent contact [CONTACT_1155] (defined as approximately 10 hours per week) who is willing to 
provide support to the subject to ensure compliance with study requirements.   
15. The subject (with support of a trial partner) must be able to follow the study procedures , receive the 
treatment in the established timeframe, and continue during the follow -up interval.   
16. The subject and trial partner must be able to understand the procedures and agree to complete the 
required a ssessments.  
17. Provide a signed and dated informed consent form (either the subject or the subject’s legal 
representative) in accordance with local regulations and/or IRB/IEC  guidelines. 
 
5.2 EXCLUSION CRITER IA 
 
An individual  will not be eligible for inclusion if any of the following criteria apply : 
1. History of blood coagulation disorders or hypercoagulability.  
2. Current use of anticoagulant therapy (e.g., heparin, warfarin, thrombin inhibitors, Factor Xa inhibitors).  Use of antiplatelet drugs (e.g., aspi[INVESTIGATOR_87494]) is acceptable. 
3. Prior hypersensitivity reaction to any human blood product or any IV  infusion; any clinically 
significant known drug allergy. 
4. Treatment with any human blood product, including transfusions and IV  immunoglobulin, during the 
6 months prior to screening. 
5. History of immunoglobulin A (IgA) or haptoglobin deficiency, stroke, anaphylaxis, or 
thromboembolic complications of IV immunoglobulins.  
6. Heart disease, as evidenced by [CONTACT_97123], unstable, new onset or severe angina, or congestive heart failure (N ew York Heart Association Class II, III , or IV) in the 6 months prior to 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 24 of 111  
 
dosing. 
7. Presence of signs and/or symptoms of hypervolemia or volume overload, including but not limited to 
pulmonary edema and/or clinically significant peripheral edema.   
8. Patients wi th recent or planned surgery sensitive to blood volume changes including 
cardio pulmonary by[CONTACT_179113].  
9. Poorly controlled high blood pressure ( BP) (systolic BP  of 160 mmHg or higher and/or diastolic BP  
of 100 mmHg or higher) despi[INVESTIGATOR_124483] 3 months prior to dosing, or treatment refractory high BP , defined as treatment requiring 3 or more antihypertensives from different 
classes.  
10. Supi[INVESTIGATOR_142642] (systolic BP  of 160 mmHg or higher and/or dias tolic BP  of > 90 mmHg when 
in a supi[INVESTIGATOR_2547]). 
11. Symptomatic orthostatic hypotension (drop in systolic BP of 20 mmHg or higher, or 30 mmHg in the presence of essential hypertension , and/or a drop in diastolic BP of 10 mmHg or higher, after 3 
minutes of standing despi[INVESTIGATOR_179090]); symptoms can include, but are not limited to, lightheadedness, visual blurring, dizziness, and/or syncope.  
12. History of Torsades de Pointes dysrhythmia. 
13. Clinically significant abnormalities on screening electrocardiogram (ECG)  including QTc intervals 
(using Fridericia’s correction form ula) of ≥ 450 ms in men and ≥ 470 ms in women. 
14. Clinically significant abnormalities on echocardiogram.  
15. Hypocalcemia of any kind, including secondary to absorption syndromes related to  gastric by[CONTACT_13786]. 
16. Current, active liver disease or known hepatic or biliary abnormalities.  
17. Uncontrolled diabetes defined as hemoglobin A1c ( HbA1c ) > 7.5%. 
18. Clinically significant abnormalities in complete blood count, complete metabolic panel, serum albumin, serum lipi[INVESTIGATOR_805], coagulation, or levels of thiamine, pyridoxine, cobalamin , and thyroid 
stimulating hormone.  
19. Positive urine drug screen.  The presence of o pi[INVESTIGATOR_2438] , benzodiazepi[INVESTIGATOR_1651], and/or amphetamines  in the 
urine drug screen may be allowed if these are prescribed and the dose stable for at least 8 weeks 
prior to screening.  
20. Hemoglobin < 10 g/dL in women and < 11 g/dL in men. 
21. Urine protein -to-creatin ine ratio (UPCR)  of > 1.[ADDRESS_210758] 30 days for small 
molecules, and 1 year for active or passive immunotherapi[INVESTIGATOR_179091].  
24. If on deep brain stimulation (DBS), DBS surgery within  12 months of screening and/or a change in 
DBS settings within [ADDRESS_210759]’s participation in the trial.  
25. Presence of a pacemaker or any other implant that would be an MRI contraindication, including DBS if not MRI compatible.  
26. More than 2 lacunar strokes or other clinically -relevant imaging abnormality on screening  MRI .  
27. Any other condition and/or situation that the investigator believes may interfere with the safety of 
the subject, study conduct, or interpretation of study data. 
 
 
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 25 of 111  
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
The Sponsor does not anticipate any specific  challenges in meeting recruitment goals of enrolling and retaining  a 
total of approximately 90 subjects in this study.  Subjects will be recruited continuously until the planned sample 
size is achieved.  Subjects who withdraw or are withdrawn during screening, as well as subjects who discontinue, may be replaced  (see Section 5.4.2 Handling of Participant Withdrawals or Termination).  
 The expected length of participation in the study of approximately [ADDRESS_210760] will be  withdraw n from  the study for the following medical or administrative reasons: 
• Occurrence of an adverse event ( AE) that represents an unacceptable risk to the subject  and when 
continued participation in the investigational study is not warranted, in the judgment of the 
investigator, Sponsor, or medical monitor .  The investigator must follow the subjec t until the AE 
resolves or is stable, unless the subject is lost to follow up. 
• Treatment with a prohibited concomitant medication other than the use of appropriate medications for the treatment of AEs under direction of the investigator. 
• Subject noncompliance, defined as refusal or inability to adhere to the trial schedule or procedures. 
• At the request of the subject or the subject’s legally authorized representative (e.g., subject  
withdraws consent), investigator, Sponsor, or regulatory authority. 
• Pregnancy. 
 
5.4.2 HANDLING OF PARTI CIPANT WITHDRAWALS OR TERMINATION    
 
Subjects will be encouraged to complete the study and all assessments.  S ubjects may voluntarily withdraw at 
any time, and the investigator may discontinue individual subjects from the study at any time.    
Approximately 90 subjects ( GRF6021: 60; placebo : 30) will be enrolled in the study with the intent of 
obtaining ~[ADDRESS_210761] visit.  The primary reason 
for study discontinuation will be documented on the case report form (CRF). 
 
  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210762] allowed the entry of microorganisms.  Neither the study agent nor the placebo  contain preservatives.  
 
6.1.4 PREPARATION 
 All vials/containers of study agent/placebo  should be inspected visually for particulate matter and 
discoloration prior to administration, whenever solution and container permit.  GRF6021 should not be mixed with protein hydrolysates or solutions containing alcohol.  The study agent and placebo should be prepared in accordance with the Infusion Administration Manual  (Appendix 11).  
 
6.1.5 DOSING AND ADMINISTRATION 
 
The study agent/placebo will be in fused in accordance with the  Infusion Administration Manual  (Appendix 
11).  The purpose of the Infusion Administration Manual  is to promote safe administration of the study 
agent /placebo ; maintain appropriate blinding of staff and study subjects; and provide guidance on the 
management  of potential risks , including but not limited to hypersensitivity reactions.  The Manual  include s 
provisions for masking the study agent /placebo and concealing the IV setup  from view of blinded staff and 
study subjects.  
 
The study agent/placebo to be administered will be dispensed  by [CONTACT_21703] (or other qualified 
personnel responsible for drug accountability) to an unblinded Infusion Nurse.  Administration of the study agent/placebo will be performed by [CONTACT_179114], and safety  measures (including AEs and 
vital signs) will be assessed by a blinded Outcomes Assessor.   
 Infusion Nurses will be qualified by [CONTACT_179115].  Only authorized Infusion Nurses may administer the study agent/placebo, and only 
subjects enrolled in the study may receive the study agent/placebo in accordance with applicable regulatory 
requirements.  
 A physician or physician -designated equivalent (e.g., physician assistant, nurse practitioner) shoul d be 
available (i.e., on site  or in the immediate vicinity ) during the entire infusion and ~ 4-hour post infusion 
monitoring period.   S/he should be qualified by [CONTACT_179116]/or experience in acute cardiac life support, or 
equivalent.  Each site must have appropriate equipment and/or medications to treat emergencies (e.g., a crash 
cart or equivalent , epi[INVESTIGATOR_238]). 
 
6.1.6 ROUTE OF ADMINISTRATION 
 The study agent and placebo will be administered by [CONTACT_167066]. 
 
6.1.7 DOSING SCHEDULE  
 
Subjects will be randomized to GRF6021 (Group 1: active dosing in both treatment periods) or placebo  
(Group 2: placebo dosing in  both treatment period s).  Subjects will receive one infusion of  per day 
for 5 consecutive days at Weeks 1 and 13.   
 
 

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210763] and their trial partner is ~[ADDRESS_210764] 
to be considered evaluable is 5 exposure days (see Section 10.3 Analysis Datasets ). 
 
6.[ADDRESS_210765] or other qualified personnel is 
responsible for ensuring adequate accountability of all used and unused study agent and placebo control agent .  
This include s acknowledgment of receipt of each shipment of study agent/ placebo  (quantity and condition)  within 
the interactive response technology (IRT) system , subject dispensing records, and returned or destroyed study 
agent/ placebo .  Dispensing records will document quantities received and quantities dispensed to subjects 
including the date dispensed, intended subject’s study identifier, initials of the individual responsible for dispensing, and  initials of the unblinded Infusion Nurse administering the study agent /placebo .  Drug 
accountability will be monitored by [CONTACT_161698] C linical R esearch A ssociate (CRA) . 
 
Accountability records must be maintained and readily available for inspection by [CONTACT_124524], 
Inc. or their designee and are open to inspection by [CONTACT_108889].  The accounts of any study 
agent /placebo  accidentally wasted or intentionally disposed of must be maintained.   
 
All unused, partially used, and used study agent/placebo should be kept securely at the site until otherwise 
instructed.  All unused, partially used, and used containers of study agent/ placebo at the site should not be 
returned or destroyed without prior written approval from the Sponsor and must be performed in accordance with the site ’s drug disposal/destruction policy, or equivalent .  The clinical study monitor will evaluate the site’s 
procedure (s) for study drug disposal/destruction in order to ensure that it complies with study requirements.  A 
copy of the site ’s drug disposal policy should be maintained or referenced in the investigator’s study file. 
 
7 STUDY PROCEDURES AND SCHEDULE 
7.1 STUDY PROCEDURES/EVALUATIONS  
 
7.1.1 STUDY SPECIFIC PROCEDURES  
 
[IP_ADDRESS] Screening Procedures During screening, the following will be performed:  
• S-STS 
• Assessment of PD , including Hoehn and Yahr  
• MHIS 
• MoCA 
• Medical history  
• Demographics  
• Review of medications  
• Vital signs  (including seated, supi[INVESTIGATOR_050], and standing BP ) 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 29 of 111  
 
• Physical examination  
• 12-Lead ECG  
• Screening Safety Lab Panel  and pregnancy test for WOCB P 
• Echocardiogram*  
• Screening MRI *  
 
*Note : it is recommended , but not required , that the echocardiogram and screening MRI be performed after 
all other screening procedures have been completed, and the subject meets all  criteria for inclusion  into the 
study.  The echocardiogram and screening MRI may be completed in any order.  
Detailed descript ions of each of these procedures are provided in the sections immediately following.  
Information pertaining to all study activities performed during screening, and the sequence of events, is provided in Section 7.3.1 Screening . 
 
[IP_ADDRESS].1 Sheehan -Suicidality Tracking Scale  
The S- STS was developed to provide a brief but efficient instrument for use in assessing change in suicidal 
ideation and behavior while providing a comprehensive description of suicidal ideation and behavior.  The 
primary goals in the design of the S- STS were for th e scale to be: 1) short and inexpensive ; 2) simple, clear, 
and easy to administer or self -rate; 3) highly sensitive (i.e., able to detect a high proportion of patients who 
are suicidal); 4) s pecific (i.e., able to screen out those who are not suicidal); 5)  sensitive to change in suicidal 
ideation and behavior; 6) c ompatible with the regulatory categories of assessment for suicidal ideation and 
behavior; 7) useful in clinical as well as research settings; 8) useful in detecting an efficacy signal for anti-suicidal medications; and 9) capable of use in pediatric and geriatric settings ( Sheehan 2014 ).  The standard 
version of the S- STS ( Appendix 7 ) is a 16 -item scale that assesses the seriousness of suicidality phenomena 
on a Likert- type scale (0 -4) ranging from  “not at all” (0) to “extremely” (4).  It also assesses the frequency of 
key phenomena and the overall time spent in suicidality.   
 
[IP_ADDRESS].2 Assessment of Parkinson’s Disease and Cognitive Impairment The diagnosis of PD  will be verified using MDS -PD criteria (Postuma 2015)( Appendix 8).  The prerequisite 
to apply the MDS -PD criteria is the  presence of parkinsonism, defined as bradykinesia, in combination with 
either rest tremor, rigidity, or both.  These features must be clearly demonstrable and not attributable to 
confounding factors ( Postuma 2015).   The stage of the disease will be classified using the Hoehn and Yahr 
scale.     
 Subjects will also be evaluated for PD -MCI  (Level I)  and PDD based on MDS crit eria ( Litvan 2012, Emre 
2007) .  PD -MCI is a syndrome defined by [CONTACT_2085], cognitive, and functional deficits ( Litvan 2012)( Appendix 
9).  The MDS criteria for MCI were developed to address issues relatively specific to PD.  The criteria were also designed to be consistent with the MDS proposed PDD criteria ( Emre 2007)(Appendix 10) and thereby 
[CONTACT_179117] .   
 Global cognition (a requisite for the diagnosis of PD- MCI Level I)  will be assessed using the MoCA 
(Nasreddine 2005)( Appendix 1)( see Section [IP_ADDRESS].1 ).  The score range for PD -MCI is 19 -25.2, and for PDD 
it is 11.4 -21.  While the score ranges overlap, differentiation between the conditions is dependent upon 
associated functional impairment  (Doerflinger 2012) .  Per the inclusion criteria for this study, subjects must 
have a MoCA score of 13-25, inclusive ( see S ection 5.1 Inclusion Criteria ). 
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 30 of 111  
 
[IP_ADDRESS].3 Modified Hachinski Ischemic Scale  
The MHIS  (Rosen 1980 ) is an [ADDRESS_210766] dementia 
from entrance into clinical trials  (an example of the full assessment for this study can be downloaded using 
the following link: Modified Hachinski Ischemia Scale ).  The scale is completed by [CONTACT_179118].  The scale takes about [ADDRESS_210767] a dementia of vascular 
etiology and thus are excluded from participating in th is trial.   
 
[IP_ADDRESS].[ADDRESS_210768]’s trial partner during screening.  The medical history should focus on recent history, with an emphasis on the history of cognitive and motor symptoms related to PD .  Additionally, the medical history should 
include: 
• Current/past illnesses and conditions 
• Current symptoms  of any active medical condition  
• Surgeries and procedures 
• Allergies  
• Family history  in biological parents, siblings, and offspring of PD, AD, or other dementias or 
neurological disorders  
• Social history (e.g. exercise, smoking, alcohol, illegal substances) and current living situation 
• Cause of parental death (if not living) 
• Prior imaging, CSF assessments, or  other relevant diagnostic test  results,  including genetics 
 
[IP_ADDRESS].[ADDRESS_210769]’s education level , ethnicity, and race will be collected by 
[CONTACT_179119]’s trial partner at screening.  
 
[IP_ADDRESS].[ADDRESS_210770]’s current medications, including 
over- the-counter drugs, herbal supplements, and/or vitamins, as well as those taken by [CONTACT_124527] 
[ADDRESS_210771] 3 months .  Assessment of eligibility should include a review of 
permitted and prohibited medications.  Any additions, discontinuation, or dosage changes in medication 
during the course of the study will be recorded.  
 
[IP_ADDRESS].7 Vital Signs  
Vital signs will include seated systolic and diastolic BP  (mmHg), heart rate (beats per minute [bpm]), 
respi[INVESTIGATOR_1487] (breaths per minute), and body temperature.  Vital signs will be measured after the subject has been seated for 5 minutes.    
In addition, at screening and at every visit during both treatment periods  (including follow-up Visits 8 and 
16), orthostatic ( supi[INVESTIGATOR_135456] ) BP will also be measured.  Orthostatics are collected as follows:  
• After a [ADDRESS_210772] is 
lying down.   
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 31 of 111  
 
• The subject should then stand for 3 minutes, if physically able or can be held in standing position 
with assistance , and the BP is taken again.   
 
At Visits 3 -7 and Visits 11-15, seated, supi[INVESTIGATOR_050], and standing BP  should be measured prior to infusion start and 
at the end of each infusion (~    post infusion start ).  Refer to the Infusion Administration 
Manual for further guidance ( Appendix 11).    
 
[IP_ADDRESS].8 Physical Examination 
A full physical examination will be performed to assess the following organ systems: skin, ENT (ears, nose, 
and throat), head, eyes, lungs/chest, heart, abdomen, musculoskeletal, extremities, neurologic and lymphatic 
systems.  The neurological exam will include cranial n erves  (visual fields, fundoscopic exam, pupi[INVESTIGATOR_179092] , extraocular muscles, facial sensation and symmetry, palate  and tongue, and head turning and shoulder 
shrug) ; motor function including m uscle strength, tone , bulk, and abnormal movements ; reflexes  (biceps, 
triceps, knees, ankles, and plantar) ; coordination ( finger -to-nose, heel -knee- shin) ; sensory f unction (light 
touch and pi[INVESTIGATOR_29107]); and gait .  Height  will be measured at screening  and weight will be monitored during the 
trial.  
[IP_ADDRESS].[ADDRESS_210773] 5 minutes in a supi[INVESTIGATOR_12251].  In some cases, it may be appropriate to repeat abnormal ECGs to rule out technical factors 
contributing to ECG artifacts or abnormality.  It is important that leads are placed in the same positions each 
time for consistency.  The overall conclusion with the interpretation of the ECGs will be recorded on the appropriate CRF.  The interpretation of the ECGs will be recorded as normal, abnormal but not clinically 
significant, or abnormal and clinically significant.  Corrected QTc intervals will be calculated using Fridericia’s correction formula.   
 
[IP_ADDRESS].[ADDRESS_210774]’s left ventricular (LV) systolic 
function to ensure the subject’s ejection fraction percentage is ≥ 55% (Gebhard 2012).   
 
[IP_ADDRESS].11 Screening Safety Lab Panel 
Biological samples will be analyzed at screening.  Samples that remain after study screening  is complete may  
be stored at the central lab  in the event additional testing (e.g., further evaluation of an AE or assessment of 
effect) is required .  Blood will be drawn by a qualified medical provider, and urine specimens will also be 
collected.  The timing and frequency for specimen collection and laboratory evaluations to be performed are further described in Section 15 Schedule of Events .  
 The labs that will be tested at screening include:  
• Serum pregnancy test in WOCBP only 
• Hematology : complete blood count ( CBC), neutrophils , total lymph ocytes , monocytes, eosinophils, 
basophils, iron, v itamin B12 (c obalamin ) 
• Chemistry : sodium, potassium, chloride, bicarbonate, blood urea  nitrogen ( BUN) , creatinine, eGFR, 
protein ( total), albumin, IgA, bilirubin [total, indirect, direct], aspartate transaminase (AST), alanine 
aminotransferase ( ALT ), gamma- glutamyl transpeptidase (GGT ), alkaline phosphatase ( ALP ), 
amylase, lipase, lactate dehydrogenase ( LDH) , creatinine kinase ( CK), glucose, HbA1C, phosphate, 

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 32 of 111  
 
magnesium, cholesterol, triglycerides, high- density lipoprotein (HDL ), low -density lipoprotein 
[LDL], haptoglobin) 
• Coagulation: (prothrombin  Time INR, prothrombin time ( PTT) , activated partial thromboplastin time 
(APTT)  
• Immunochemistry: thyroid- stimulating hormone ( TSH  ultrasensitive), hepatitis B surface antigen  
(HBsAg ), hepatitis C antibody ( HCV Ab ), Human immunodeficiency virus antibody ( HIV Ab , HIV -
1/HIV -2), brain natriuretic peptide ( BNP ) 
• Urinalysis : specific gravity, pH, glucose, protein, ketones, bilirubin, urobilinogen, hemoglobin, 
leucocyte esterase, nitrite, white blood cells (WBC), red blood cells ( RBC), hyaline casts, granular 
casts, waxy casts, WBC casts, epi[INVESTIGATOR_1663], bacteria, color, sam ple aspect  
• Urine c hemistry : protein, microalbumin, c reatinine , sodium, p otassium , microalbumin/c reatinine , 
protein/ creatinine ratio , sodium/c reatinine ratio , potassium/ creatinine ratio  
• Urine drug screen : cocaine, amphetamines, barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids, opi[INVESTIGATOR_858], 
phencyclidine, propoxyphene, methadone 
• Other testing : direct antiglobulin test, ionized calcium, vitamin B6 (pyridoxine) , vitamin B1  
(thiamine ), and C1 i nhibitor * 
 *Note: Results of the C1 inhibitor test are not required for eligibility, and thus need not be available 
prior to randomization and dosing.   
 
[IP_ADDRESS].12 Magnetic Resonance Imaging  
The s creening MRI is required and will  assess for  lacunar strokes and other abnormalities ( see Section 5.2 
Exclusion Criteria ).   
 [IP_ADDRESS] Procedures to Assess Safety 
Subjects enrolled in the trial will be monitored closely to assess safety and tolerability of the study agent and 
intervention.  Study- specific procedures that will be used for this purpose are summarized below.  
Information regarding the timing and frequency of these procedures is provided in Section 7.3 Study 
Schedule .  
• Review of AEs  
• Review of medications  
• Vital signs  
• Weight  
• S-STS 
• 12-Lead ECGs  
• Targeted physical exam s  
• End of Study (or Early Termination) physical exam 
• Blood draw and urine collection for l aboratory evaluations 
 
[IP_ADDRESS].1 Review of Adverse Events 
AEs will be reviewed, documented, and reported as required at each visit, beginning at S creening .  For 
definitions, guidance, and additional information regarding AEs, refer to Section 8 .  
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 33 of 111  
 
[IP_ADDRESS].[ADDRESS_210775]’s current medications, including over- the-counter 
drugs, herbal supplements and/or vitamins, as well as those taken by [CONTACT_124528].  Changes 
to the subject’s list of medications should be reviewed and recorded.  Review of medications should occur at every visit.  
 
[IP_ADDRESS].3 Vital Signs 
Refer to Section [IP_ADDRESS]. 7 for a description of vital s igns.  Vital signs will be collected at every visit (see the  
Schedule of Events ) with additional measurements during each treatment period.  During infusions, vital signs 
will be collected according to the  Infusion Administration Manual  (Appendix 11) by [CONTACT_179120].    
 
[IP_ADDRESS].4 Sheehan -Suicidality Tracking Scale  
Refer to Section [IP_ADDRESS].1 for a description of the S- STS.  
 [IP_ADDRESS].5 12- Lead ECG  
Refer to  Section [IP_ADDRESS].9 for information pertaining to 12- Lead ECGs.  
 [IP_ADDRESS].6 Targeted Physical Exams 
A targeted physical exam, including auscultation of the heart and lungs, an assessment of peripheral edema, 
and weight will be performed per the Study Schedule in Section 7.3.    
 
[IP_ADDRESS].7 Physical Exam 
Refer to Section [IP_ADDRESS]. 8 for a description of the Physical Exam.  The physical exam, including 
measurements of height and weight, will be performed at screening.  The physical exam and weight 
measurement will be  repeated at End of Study (or early termination).   
 
[IP_ADDRESS].[ADDRESS_210776] blood and urine specimens collected for clinical evaluation  and safety monitoring.  
Samples that remain may be stored at the central lab in the event additional testing (e.g., further evaluation of 
an AE or assessment of effect) is required .  The timing and frequency of labs for  clinical evaluation and  safety 
monitoring  are provided below and specified in  Section 15 Schedule of Events .  
 
[IP_ADDRESS].8.1 Pregnancy Testing  
For WOCBP, s erum and/or urine pregnancy testing should be conducted at Visits 3 and 11 with results 
available prior to infusion start.  
[IP_ADDRESS].8.2 Pre -infusion Safety Labs  
Pre-infusion Safety Labs will be performed  at each site’s local lab oratory  or via an i -STAT Handheld Blood 
Analyzer.  When sending samples to the local laboratory, s amples for the Pre -Infusion Safety Labs should be 
collected prior to infusion start on Visits 3, 4, 6, 11, 12, and 14. This is to  allow sufficient turn -around time 
for local laboratories to receive, process, and report results prior to the subject’s next infusion. When using an 
i-STAT Handheld Blood Analyzer, the blood sample(s) may be obtained on the same day as the infusion, provi ded that all Pre -infusion Safety Lab results are available and interpre ted prior to the subject’s infusion 
start on Visits 4, 5, 7, 12, 13, and 15.   
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 34 of 111  
 
 Pre-infusion Safety Labs include: 
• Sodium  
• Potassium  
• Ionized calcium  
• BUN  
 • Creatinine  
• Hematocrit  
• Hemoglobin  
• Platelets * 
 
*Please note that the i -STAT Chem 8+ test cart ridges  can perform all Pre -Infusion Safety Labs with the 
exception of the platele t count. The plate lets lab will need to be obtained and assessed via the site’s local 
laboratory prior to the next day’ s infusion .   
 
[IP_ADDRESS].8.3 Comprehensive Labs  
Samples for Comprehensive Labs will be collected prior to infusion start on Visits 6 and 14 as well as during 
follow-up on Visits 8, 9, 16, and 17.  These include:  
• Hematology : CBC, neutrophils, total lymphocytes, monocytes, eosinophils, basophils, and iron  
• Chemistry : sodium, potassium, chloride, bicarbonate, BUN, creatinine, eGFR, protein ( total), 
albumin, IgA, bilirubin ( total, indirect, direct ), AST, ALT, GGT, alkaline phosphatase, amylase, 
lipase, LDH, CK, glucose, phosphate, magnesium, cholesterol, triglycerides, HDL, LDL 
• Coagulation: prothrombin t ime/international normalized ratio PT/ INR, PT T, APTT 
• Urinalysis: specific gravity, pH, glucose, protein, ketones, bilirubin, urobilinogen, hemoglobin, 
leucocyte esterase, nitrite, WBC, RBC, hyaline casts, granular casts, waxy casts, WBC casts, epi[INVESTIGATOR_1663], bacteria, color, sample aspect  
• Urine chemistry : microalbumin, creatinine, sodium, potassium, microalbumin/creatinine, 
sodium/creatinine ratio, potassium/creatinine ratio  
• Ionized calciu m 
 
[IP_ADDRESS].8.4 Exit Safety Lab Panel 
The labs that will be tested as part of the Exit Safety Lab Panel  include:  
• Hematology: CBC, neutrophils, total lymphocytes, monocytes, eosinophils, basophils, and iron 
• Chemistry : sodium, potassium, chloride, bicarbonate, BUN [urea], creatinine, eGFR, protein ( total), 
albumin, IgA, bilirubin ( total, indirect, direct ), AST, ALT, GGT, alkaline phosphatase, amylase, 
lipase, LDH, CK, glucose, phosphate, magnesium, cholesterol, triglycerides, HDL, LDL 
• Coagulation: PT/INR, PT T, APTT)  
• Immunochemistry: HBsAg, HCV Ab, HIV Ab  (HIV- 1/HIV -2) 
• Urinalysis : specific gravity, pH, glucose, protein, ketones, bilirubin, urobilinogen, hemoglobin, 
leucocyte esterase, nitrite, WBC, RBC, hyaline casts, granular casts, waxy casts, WBC casts, 
epi[INVESTIGATOR_1663], bacteria, color, sample aspect  
• Urine chemistry : microalbumin, creatinine, sodium, potassium, microalbu min/creatinine, 
sodium/creatinine ratio, potassium/creatinine ratio  
• Other testing : direct antiglobulin test, ionized calcium  
 
[IP_ADDRESS] Procedures to Assess Efficacy 
Procedures to assess efficacy include cognitive and motor function testing.   Information regarding the timing 
and frequency of these procedures is provided in Section 15 Schedule of Events . 
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210777]’s participation unless a change in rater is unavoidable.  When possible, a ll cognitive 
and motor testing should be performed when the subject is in the “ON” state and  at approximately the same 
time after the last dose of each  subject’s PD medication (s).  The preferred  order of behavioral and cognitive 
testing during visits with multiple assessments is  as follows :  
1. MoCA  
2. CDR -CCB  
3. D-KEFS  
4. dCDT  
5. MDS -UPDRS  1/2/3 
6. SE-ADL  
7. CISI -PD 
8. PDQ-39  
9. GDS -15 
 
Descriptions of each neuropsychological and motor function assessment are provided below. 
 
[IP_ADDRESS].1 Montreal Cognitive Assessment  
The MoCA ( Nasreddine 2005)(Appendix 1) is a commonly used screening test easily administered by 
[CONTACT_179121].  It assesses the domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.  The total possible 
score is 30 points with a score of 26 or more considered normal.   
 
[IP_ADDRESS].[ADDRESS_210778] widely used automated cognitive function assessment system i n clinical research  
worldwide ( Wesnes 1977, Wesnes 2000 , Wesnes 2013) .  It was developed to assess both enhancement and  
impairment of human cognitive function.  There are several core tests available.  The core tests have remained 
constant over the last three decades while being steadily supplemented with others as required.  In this study, 
the following will be measured us ing the CDR -CCB system: Continuity  and Power of Attention, Working 
Memory, and Epi[INVESTIGATOR_17120] .  Subjects will have two CDR -CCB training sessions during the screening 
period to ensure adequate performance at the B aseline Visit (Visit 2).   
 
[IP_ADDRESS].[ADDRESS_210779] is used for assessment o f executive function, which is one of the main 
cognitive domains impaired in PD ( Delis 2001 , Delis 2004, Emre 2004) (an example of the full assessment 
for this study can be downloaded using the following link: Delis -Kaplan Executive Function Verb al Fluency ).  
The D -KEFS Verbal Fluency Test has three conditions: Letter Fluency, Category Fluency, and Category 
Switching.  In the Letter Fluency condition, subject s are asked to say as many words that start with a 
particular letter (e.g., F, A, S) as possible over three trials of [ADDRESS_210780] s to say as many words belonging to a particular semantic category (e.g., animals, tools) as 
they can in two trials of 60 seconds.  In the final condition, subjec ts are  asked to switch between words 
belonging to two different semantic categories in one trial of 60 seconds (e.g., fruits and furniture).  The test requires subjects  to exercise mental flexibility , avoid perseverative responses, and engage in an effective and 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210781] -CCB, which does not include assessments in this critical cognitive domain .   
 
[IP_ADDRESS].[ADDRESS_210782]  and easy -to-perform screening 
instrument for the early detection of cognitive impairment (Müller 2017 ).  The pen -like dCDT device gathers 
the x- y coordinates that describe the movement of the stylus as it chan ges its position during the assessment .  
It also assesses when the stylus or writing device is not exerting pressure on the writing surface (i.e., in -air 
movements performed by [CONTACT_179122]), making it a more sen sitive 
tool than the conventional clock test with increased diagnostic accuracy ( Müller 2017).  
 
[IP_ADDRESS].5 Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale  
The MDS -UPDRS ( Fahn 1987, Movement Disorder Society Task Force 2003)( Appendix 2) was developed in 
an effort to incorporate elements from existing scales to provide a comprehensive but efficient and flexible 
means to monitor PD-related disability and impairment.  The MDS- UPDRS has four components (Part 1, 
Mentation, Behavior, and Mood; Part 2, Activities of Daily Living; Part 3, Motor; Part 4, Complications).  
Parts [ADDRESS_210783] widely used for both clinical and research purposes.  One of the core advantages of the UPDRS is that it was developed as a compound scale to capture multiple aspects of  PD.  It assesses both 
motor disability (Part 2) and motor impairment (Part 3).  In addition, Part 1 addresses mental  dysfunction and 
mood.  The rating for each item is from 0 (normal) to 4 (severe).  The total score for each Part is obta ined 
from the sum of the corresponding item scores.  For this study, Parts 1-3 will be completed, and t he estimated 
time for completion is 20-30 minutes. 
 
[IP_ADDRESS].6 Schwab and England Activities of Daily Living Scale 
The SE-ADL evaluates patients’ perceptions of global functional capacity and dependence ( Schwab 
1968)( Appendix 3 ).  Scoring is expressed in terms of percentage, in 10 steps from 100 to 0 (100%, normal 
status; 0%, bedri dden with vegetative dysfunction), so that the lower the score, the worse the functional 
status.  The rating is made by a  trained clinician.  
 
[IP_ADDRESS].7 Clinical Impression of Severity Index – Parkinson’s Disease  
The CISI -PD is a severity index formed by [CONTACT_179123] (motor signs, disability, motor complications, and 
cognitive status), rated 0 (not at all) to 6 (very severe or completely disabled) ( Martinez -Martin 
2006)( Appendix 4 ).  A total score is calculated by [CONTACT_179124].  The scale is completed by a 
clinician.  It only takes a few minutes to complete once the state of the subject  is known.  
 
[IP_ADDRESS].8 Parkinson’s Disease Quality of Life Questionnaire-39 
The PDQ- 39 is a self -administered questionnaire of 39 questions relating to 8 key areas of health and daily 
activities, including both motor and non- motor symptoms ( Peto 1998 )(Appe ndix 5 ).  The eight dimensions 
include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, 
communication, and bodily discomfort.  It is scored on a scale of 0 -100 with lower scores indicating better 
health and high scores indicating more severe symptoms.     
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 37 of 111  
 
[IP_ADDRESS].[ADDRESS_210784] week ( Yesavage 1983)( Appendix 6).  Questions from the long form GDS which had the highest correlation 
with depressive symptoms in  validation studies were selected for the short version which is more easily used 
by [CONTACT_179125]/or feel easily fatigued.  Of the 
[ADDRESS_210785] (question numbers 
1, 5, 7, 11, 13) indicate depression when answered negatively.  It takes about 5 to 7 minutes to complete. 
 
7.2 LABORATORY PROCEDURES/EVALUATIONS  
 
7.2.1 CLINICAL LABORATORY EVALUATIONS  
 
Biological samples (e.g. whole blood, serum, urine) will be collected for laboratory evaluations in accordance 
with Section [IP_ADDRESS].11 Screening Safety Lab Panel , Section [IP_ADDRESS].8 Blood and Urine Collection for Lab 
Evaluations , and the Schedule of Events .  .  Clinical sample processing and laboratory evaluations will be 
conducted by a central lab’s registered and certified Clinical Laboratory Improvement Amendments (CLIA) facilities.  Pre -infusion laboratory evaluations will be conducted at the clinical site.  Refer to the study’s 
laboratory manual for complete information regarding all laboratory evaluations to be performed, sample collection procedures, and related requirements.  
 
The investigator is responsible for determining and documenting whether  out of ra nge laboratory values are 
clinically significant.  All clinically significant values will be recorded as AEs in the CRF and followed until determined to be stable or resolved , unless the subject is lost to follow up.  Once resolved, the appropriate 
CRF pag e(s) will be updated.
  
 
7.2.2 OTHER TESTS  OR PROCEDURES  
 
[IP_ADDRESS]  Apolipoprotein E (ApoE) Genotype Testing   
ApoE genotype is a known risk factor for neurodegeneration and dementia pathogenesis, with presence of the 
ApoE ε4  allele carrying increased risk.  This risk is further influenced by [CONTACT_654], sex, race, and ethnicity.  Thus, 
determining ApoE genotype at baseline will allow for the assessment of possible differential effects of Apo E 
genotype on safety, treatment efficacy, neuroimaging, and other exploratory measures.  DNA for ApoE  
analysis will be obtained from a blood serum sample  collected during Visit [ADDRESS_210786]’s first 
infusion.  
[IP_ADDRESS]  Magnetic Resonance Imaging MRI will be used to evaluate subjects’ eligibility for inclusion in the study  at screening.  Structural i mages  
will be interpreted by a central reader at screening and any exclusionary findings will be reported.  Where 
available, functional imaging will also be acquired to assess for functional connectivity as measured by  [CONTACT_179126]-
fMRI and cerebral blood flow as measured by  [CONTACT_179127].  In consenting subjects, an additional MRI at Visit 
[ADDRESS_210787] will be asked to lie on a 
narrow bed in a large tunnel while images are captured by [CONTACT_179128].  Participation in the scree ning 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 38 of 111  
 
MRI is required , while participation in the additional MRI at Visit 16 is optional and not required for 
inclusion in the study. 
 
[IP_ADDRESS]  Proteomic and Genetic Biobanking  
Blood samples will be collected for biobanking  during Visits 3 and 11 (prior to infusion) , all follow -up visits 
(Visits 8 -10, 16- 18), and End of Study (Visit 19) or Early Termination Visit.  For  more  information regarding 
the timing and procedures for sample collection and related requirements, refer to the study’s laboratory 
manual and  Section [ADDRESS_210788] overview of the proteins that are present in 
the plasma sample by [CONTACT_58833] 1000 -5000 analytes and allow generation of a proteomic signature.  From this 
signature, it is hoped that key proteins that are drivers of cognitive function and/or indicators of disease 
progression can be identified .  Blood samples will be collected  for analysis of emergent genetic markers of 
disease.  By [CONTACT_124533], the goal is to 
identify the biomarkers relevant to further optimizing treatment in PD, PD -MCI, and PDD.  For information 
regarding future use of stored samples, see Section 12.5 Future Use of Stored Specimens . 
 
7.2.3 SPECIMEN PREPARATION, HANDLING, STORAGE, AND SHIPPI[INVESTIGATOR_179093]’s laboratory manual for specimen preparation, handling, storage, and shippi[INVESTIGATOR_4585].  
 
7.3 STUDY SCHEDULE  
 To ensure follow -up visits occur at approximately the same intervals following both treatment periods, visit 
windows should be calculated as follows: 
 
• Visit  windows fo r Visits 1 -10 should be calculated relative to Day 1. 
• Visit windows for Visits 11 -19 should be calculated relative to Day 85 ±7 (i.e., first day of dosing for 
Treatment Period 2). 
 
Study visit procedures are listed in the recommended order in which they should be completed. 
 
7.3.1 SCREENING  
 Visit 1, Screening Visit (Day -35 to -8)  
□ Informed consent of subject (or the subject’s legally authorized representative) as documented by a  
signed and dated informed consent form  must be obtained prior to any study- related assessments.  
□ Administer the S- STS. 
□ Administer the MoCA . 
□ Administer the MHIS . 
□ Verify diagnosis of PD according to MDS criteria , including Hoehn and Yahr stage. 
□ Verify diagnosis of PD- MCI or PDD according to the consensus criteria . 
□ Obtain medical history, including medical records  and test results  to support PD,  PD-MCI , or PDD 
diagnosis if available. 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 39 of 111  
 
□ Collect demographic information. 
□ Review subject’s current and prior medications. 
□ Review and provide the subject (and subject’s trial partner) with a list of permitted and prohibited medications.  
□ Collect vital signs  (including sitting, supi[INVESTIGATOR_050], and standing BP ), height, and weight. 
□ Perform a complete  physical and neurological exam . 
□ Perform 12 -lead ECG.  
□ Collect blood and urine samples required  for the Screening Safety Lab Panel.  
□ Perform transthoracic echocardiogram.  
□ Complete screening MRI  scan .  
□ Verify that the subject fulfills all of the inclusion criteria and none of the exclusion criteria. 
 
During the screening period, subjects should complete two training sessions with the CDR -CCB system prior 
to baseline testing at Visit 2.  The two training sessions may be scheduled at any time during the screening window. 
 
Note : The Screening Visit may be split to allow for sufficient time to complete all required procedures.  
Review AEs and concomitant medications during split visits, as applicable.   
 
7.3.2 RANDOMIZATION  
 
Subjects will be randomized after eligibility has been confirmed  (including MRI and echocardiography 
results) . 
 
7.3.3 BASELINE  
 Visit 2, Baseline (Days - 7 to -1) 
□ Re-review screening assessments for eligibility.  
□ Review AEs and concomitant medications.  
□ Collect vital signs.  
□ Ensure the subject has had an opportunity to eat a meal or snack prior to commencing cognitive and 
motor testing  and that the subject is in the ON state .  PD medications  should be taken at the standard 
intervals for each subject  and testing should be s cheduled to facilitate the subject being in the ON 
state. 
□ It is preferred that cognitive and motor function testing is performed  in the following order  (breaks are 
permitted between assessments as needed) : 
1. CDR -CCB  
2. D-KEFS  
3. dCDT  
4. MDS -UPDRS  1/2/3  
5. SE-ADL  
6. CISI -PD 
7. PDQ-39 
8. GDS -15 
  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 40 of 111  
 
7.3.4 TREATMENT  
 There are two treatment periods scheduled during the trial.  During each  treatment period, subjects will 
receive a total of 5  infusions  of their assigned treatment (i.e., either GRF6021 or placebo) .  It is anticipated 
that sites will infuse subjects with 5 doses over 5  consecutive days.  A “grace day” is allowed in the event of 
unanticipated safety or health concerns during each treatment period.  
 Visits 3 -7 (Days 1- 5) and 11- 15 (Day 85*-89 ): 
*Day 85 has a ± 7-day window 
□ Perform the following procedures prior to administering study treatment:  
o Review AEs and concomitant medications. 
o Obtain blood and urine samples for Comprehensive Labs  (Visits 6 and 14 Only ); fasting samples 
preferred . 
o Obtain samples for proteomics/epi[INVESTIGATOR_7009]/biobanking; fasting samples preferred ( Visits 3 and 11 
Only ). 
o Obtain sample for ApoE testing ( Visit 3 Only ). 
o For WOCBP  Only : perform  pregnancy testin g and review results (Visits 3 and 11 Only ). 
o Obtain P re-infusion S afety Lab samples and assess results prior to  the next day’s infusion  (Visits 
3, 4, 6, 11, 12, and 14 Only). When using an i -STAT Handheld Blood Analyzer, the blood 
sample(s) may be obtained on the same day as the infusion (Visits 4, 5, 7, 12, 13, and 15 ). 
o Perform  targeted physical exam (i.e. auscultation of heart and lungs and assessment of peripheral 
edema)  (Visits 3, 5, 7, 11, 13, and 15 Only ). 
o Measure body weight in kilograms. 
o Perform  12-lead ECG ( Visit  7, 11, and 15 Only ). 
o Administer the S- STS ( Visit 3 Only ). 
o Collect vital signs  (including sitting, supi[INVESTIGATOR_050], and standing BP ).  
□ Administer study treatment and perform safety assessments per the Infusion Administration Manual 
(Appendix 11 ). 
□ Administer the S -STS after the subject’s final infusion ( Visit  7 Only ).  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 41 of 111  
 
7.3.5 FOLLOW -UP 
 Visits 8 and 16 (Day  6 + 3 Days and Day 90 + 7 Day s): 
□ Review AEs and concomitant medications. 
□ Collect the following:  
o Vital signs (including sitting, supi[INVESTIGATOR_050], and standing BP ) and subject’s weight in kilograms. 
o Blood and urine samples for Comprehensive L abs (fasting samples preferred) . 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred) . 
□ Ensure the subject has had an opportunity to eat a meal or snack prior to commencing cognitive and 
motor testing and that the subject is in the ON state.  PD medications should be taken at the standard 
intervals for each subject and testing should be scheduled to facilitate the subject being in the ON 
state.  
□ It is preferred that  cognitive and motor function testing is performed in the following order  (breaks 
are permitted between assessment s as needed) :  
1. CDR -CCB  
2. D-KEFS  
3. dCDT  
4. MDS -UPDRS  1/2/3 
□ Consenting subjects will undergo an additional MRI scan  (Visit 16  + 7 days Only ). 
 
Note : Visit 16 (Day 90) may be split to allow for sufficient time to complete all required procedures. Review 
AEs and concomitant medications during split visits, as applicable.   
 
Visit 9 (Days 28 ± 7 Days) and Visit 17  (Day  112 ± 7 Days ): 
□ Review AEs and concomitant medications.  
□ Collect the following:  
o Vital signs . 
o Blood and urine samples for Comprehensive L abs (fasting samples preferred) . 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred) . 
□ Ensure the subject has had an opportunity to eat a meal or snack prior to commencing cognitive and 
motor testing and that the subject is in the ON state.  PD medications should be taken at the standard 
intervals for each subject and testing should be scheduled to facilitate the subject being in the ON 
state.  
□ It is preferred that  cognitive and motor function testing is performed in the following order (breaks are 
permitted between assessment s as needed) :  
1. MoCA 
2. CDR -CCB  
3. MDS -UPDRS  1/2/3 
4. PDQ-39 ( Visit 9 Only)  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 42 of 111  
 
Visit 10 (Day 56 ± 7 Days) and Visit 18 (Day 140 ± 7 Days): 
□ Review AEs and concomitant medications.  
□ Collect the following:  
o Vital signs . 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred) . 
□ Ensure the subject has had an opportunity to eat a meal or snack prior to commencing cognitive and motor testing and that the subject is in the ON state.  PD medications should be taken at the standard 
intervals for each subject and testing should be scheduled to facilitate the subject being in the ON state.  
□ It is preferred that  cognitive and motor function testing be performed  in the following order (breaks are 
permitted between assessments as needed) :  
1. CDR -CCB  
2. D-KEFS  
3. dCDT  
4. MDS -UPDRS  1/2/3 
5. SE-ADL  (Visit 10 Only ) 
6. CISI -PD (Visit 10 Only ) 
7. PDQ-39 
8. GDS -15 
 
7.3.6 FINAL STUDY VISIT  
 Visit 19, End of Study  (Day 168 ± 7 Days )  
□ Review AEs and concomitant medications.  
□ Collect the following:  
o Vital signs and subject’s weight in kilograms. 
o Blood and urine samples for Exit Safety Lab P anel (fasting samp les preferred) . 
o Samples for proteomics/epi[INVESTIGATOR_7009]/biobanking (fasting samples preferred) . 
□ Perform the physical exam.  
□ Ensure the subject has had an opportunity to eat a meal or snack prior to commencing cognitive and 
motor testing and that the subject is in the ON state.  PD medications should be taken at the standard 
intervals for each subject and testing should be scheduled to facilitate the subject being in the ON 
state.  
□ It is preferred that  cognitive and motor function testing be performed  in the following order (breaks are 
permitted between assessments as needed) :  
1. CDR -CCB  
2. MDS -UPDRS  1/2/3 
3. SE-ADL  
4. CISI -PD 
5. PDQ-39  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210789] two infusions of GRF6021 /placebo . 
 
7.3.8 SCHEDULE OF EVENTS TABLE  
 
A tabular summary of all procedures that will be accomplished at each study visit can be found in Section 15 
Schedule of Events.  
 
7.4 CONCOMITANT MEDICATIONS  
 
All concomitant prescription medications taken during study participation will be recorded on the CRFs.  For this protocol, a prescription medication is defined as a medication that can be prescribed only by a properly authorized/licensed clinician.  Medications to be reported in the CRF are concomitant prescription medications, 
over- the-counter medications , and non- prescription medica tions. 
 
7.5 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES  
 
The following concomitant medications , treatments, and procedures are prohibited:  
• Concurrent participation in any other therapeutic treatment trial.  If there was prior clinical trial 
particip ation, subject must have discontinued investigational agents for at least 30 days for small 
molecules, and 1 year for active or passive immunotherapi[INVESTIGATOR_167035].  
• Use of an anticoagulant therapy (e.g., heparin, warfarin, thrombin inhibitors, Fact or Xa inhibitors).  Use 
of antiplatelet drugs (e.g., aspi[INVESTIGATOR_87494]) is acceptable. 
• Any drugs of the interferon class. 
• Systemic cortico steroids (e.g., hydrocortisone, cortisone, betamethasone, prednisone, prednisolone, 
triamcinolone, dexamethasone, fludrocortisone) for longer than 5 consecutive days .  Ophthalmic, topi[INVESTIGATOR_2855], 
intra-articular , and inhaled steroids are allowed.  
• If on DBS, a change in DBS settings at any point during the subject’s participation in the trial.  
 
[ADDRESS_210790] is essential.  Any instances of unblinding 
will be managed as indicated  in Section 10.6.3 Breaking the Study Blind/ Subject  Code.  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
 
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)  
 
Per 21 CFR 312.32(a) an AE  is any untoward (unfavorable, harmful, or pathologic) medical occurrence in a 
subject administered a pharmaceutical (investigational) product even if the event does not necessarily have a 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 44 of 111  
 
causal relationship with this treatment .   
 
An AE can therefore be an y unfavorable and unintended sign (including an abnormal laboratory finding that 
is deemed clinically significant), symptom, or disease temporally associated with the use of a medicinal 
(investigational) product whether or not related to the medicinal (i nvestigational) product .   
 
An AE does include any:  
• Exacerbation of a pre-existing illness. 
• Subjective or objective symptoms spontaneously offered by [CONTACT_3184]/or observed by [CONTACT_119114]. 
• Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_3756]. 
• Condition detected or diagnosed after study drug administration even though it may have been present prior to the start of the study (unless it can be demonstrated by [CONTACT_179129]/time of Informed Consent). 
• Continuous persistent disease or symptoms present at baseline that worsen following the start of the study. 
• Symptoms associated with disease not previously reported by [CONTACT_423]. 
• Untoward medical occurrences considered by [CONTACT_110190] -mandated 
procedures. 
• Abnormal assessments (e.g., change on physical examination, ECG findings), if they represent a clinically significant finding, that were not present at Baseline or worsened during the course of the study. 
• Laboratory test abnormalities, if they represent a clinically significant finding, symptomatic or not, which were not present at Baseline or worsened during the course of the study . 
 
An AE DOES NOT include a/an:  
• Elective medical or surgical procedure (e.g., surgery, endoscopy, tooth extraction, transfusio n).  
• Pre-existing diseases or conditions present or detected at the start of the study that do not worsen. 
• Situations where an untoward medical occurrence has not oc curred (e.g., hospi[INVESTIGATOR_124492], social and/or convenience admissions) . 
• The disease or disorder being studied , or sign or symptom associated with the disease or disorder , 
unless more severe than expected for the subject’s condit ion. 
• Overdose of either study drug or concurrent medication without any signs or symptoms. 
• Symptoms associated with PD, PD -MCI, and PDD that are consistent with the subject’s usual 
clinical course unless the symptom(s) meet(s) the criteria for “serious.” 
• Pregnancy.  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 45 of 111  
 
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
Note : if either the investigator or the Sponsor believes that the event is serious, the event must be considered 
serious and evaluated for expedited reporting.   
Note : the terms “severe” and “serious” are not synonymous.  Severity (or intensity) refers to the grade of an 
AE.  “Serious” is a regulatory definition.   
A serious adverse event (experience) or reaction is an untoward medical occurrence that , at any dose, fulfills 
one or more of the following criteria:  
a. Results in death (i.e., the AE actually causes or leads to death).  
b. Is life -threatening . 
• An AE  is considered “life-threatening” if, in the view of either the investigator or Sponsor, its 
occurrence places the patient or subject at immediate risk of death; it does not include AEs  which, 
had it occurred in a more severe form, might have caused death.  
c. Results in inpatient hospi[INVESTIGATOR_1081].  
• Hospi[INVESTIGATOR_5187] a pre- existing condition that did not worsen during the study 
is not con sidered an AE ; hospi[INVESTIGATOR_179094].  
• Complications that occur during hospi[INVESTIGATOR_1084]; if a complication prolongs hospi[INVESTIGATOR_059], 
the event is an SAE.  
• “Inpatient” hospi[INVESTIGATOR_124493] a hospi[INVESTIGATOR_167042]; it does not include presentation at a casualty or emergency room unless the event meets the definition of an Important Medical Event (in the opi[INVESTIGATOR_12182]).  
d. Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life 
functions.  
• The term ‘disability’ means a substantial disruption of a person’s ability to conduct normal life functions; this definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, accidental 
trauma (i.e., sprained ankle) that may interfere or prevent everyday life func tions but do not constitute 
a substantial disruption . 
e. Results in a congenital anomaly in the offspring of a subject who received drug.  
f. Results in an Important Medical Event.  Important Medical Events are events that may not result in death, 
be life -threatening, or require hospi[INVESTIGATOR_124495], based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgica l intervention to 
prevent one of the outcomes listed in this definition; examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpa tient hospi[INVESTIGATOR_059], or the development of drug dependency or drug 
abuse.  
• Medical and scientific judgment should be used in deciding whether prompt reporting is appropriate 
in this situation . 
  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 47 of 111  
 
mentioned as occurring with the particular drug under investigation.  For example, although angioedema is anticipated to occur in some patients exposed to drugs in the a ngiotensin -converting enzyme ( ACE ) inhibitor 
class and angioedema would be described in the Investigator ’s Brochure as a class effect, the first case of 
angioedema observed with the drug under investigation should be considered unexpected for reporting purposes ( FDA 2012).  
 This definition of “unexpected” relies entirely on the Reference Safety Informatio n in the Investigator ’s 
Brochure as the basis for determining if newly acquired information generated from clinical trials or reported from other sources is unexpected .  The suspected adverse reactions listed in the Investigator ’s Brochure (i.e., 
“expected”) are those observed with the investigational drug and for which a causal relationship between the 
event and the drug is suspected or confirmed.  
 Sponsor assessment of expectedness and relationship to study drug/causality will determine the need for 
expedited reporting of AEs.  
 
8.3 TIME PERIOD/FREQUENCY FOR EVENT ASSESSMENT/FOLLOW -UP 
 
At every clinic visit, subjects will be assessed for AEs and SAEs.  After the subject has had an opportunity to spontaneously mention any problems, the investigator should inquire about AEs by [CONTACT_7939] a non-leading question 
such as the following:  
1. “How are you feeling?”  
2. “Have you had any changes since your last assessm ent/visit?”  
3. “Have you taken any new medicines since your last assessment/visit?”  
 
8.3.[ADDRESS_210791] completes the study (or has their last visit) that the investigator judges may be reasonably 
related to study treatment or study participation.  
 
8.[ADDRESS_210792] be described as follows: the date of onset, date of resolution, 
severity (mild, moderate, severe), frequency of the event (single epi[INVESTIGATOR_1865], intermittent, continuous), action 
taken with study treatment (no action taken, treatment held, treatment discontinued), outcome, causality* 
(unrelated, possibly related, definitely related), and seriousness criteria.  Each AE or suspected adverse reaction must be recorded separately.  
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 48 of 111  
 
*Note : Causality assessment will be made only when the AE occurs after the subject has initiated at least one 
infusion of the study agent.  An AE occurring before the subject’s exposure to study agent will always be 
labeled as “unrelated”.  
 
Any AE occurring during the study must be documented in the subject’s medical records and as an AE in the 
CRF.  Any SAE occurring during the study must be documented in the subject’s medical records and as an SAE in the CRF.  
 A separate set of SAE pages should be used for each SAE.  However, if at the time of initial reporting, multiple SAEs are present that are temporally and/or clinically related, they may be reported on the same SAE 
page.  
 The investigator should attempt to establish a diagnosis of the event (that meets the definition of an AE or 
SAE) bas ed on signs, symptoms, and/or other clinical information.  In such cases, the diagnosis should be 
documented as the AE and/or SAE and not the individual signs or symptoms.  The diagnosis will become the basis for the verbatim term as reported by [CONTACT_3170].  If no diagnosis is known and clinical signs and 
symptoms are not present, the abnormal finding should be recorded.  
 In addition to the i nvestigator’s own description of the AE , each AE will be encoded according to the 
MedDRA . 
 The investigator will take all appropriate and necessary therapeutic measures required for resolution of the 
AE.  Any medication necessary for the treatment of an AE must be recorded on the concomitant medication 
CRF .   
 
The SAE pages of the CRF should be completed as thoroughly as possible and signed by [CONTACT_15009]/her designee before transmittal to the study Contract Research Organization (CRO).  It is very important 
that the investigator provide his/her assessment of causality to study drug as well as an applicable diagnosis at 
the time of the initial SAE report.  
 
8.4.2 SERIOUS ADVERSE EVENT REPORTING  
 
[IP_ADDRESS] Timeframes for Reporting SAEs  
 The Sponsor will notify the FDA a s well as the competent authority of each participating country, including 
the Agence Nationale de Sécurité du Médicament et des Produits de Sant é (ANSM) , Therapeutic Goods 
Administration  (TGA) , and all participating investigators in a safety report of potentially serious risks from 
clinical trials ( i.e., Suspected Unexpected Serious Adverse Reactions [S[LOCATION_003]R s]), as soon as possible after the 
Sponsor receives the safety information and determines t hat the information qualifies for reporting:  
• No later than 7 calendar days for events that are life threatening (in the opi[INVESTIGATOR_124496]) or that involve death as an outcome. 
• No later than 15 calendar days for all other S[LOCATION_003]Rs. 
 
As such, prompt notification of the Sponsor, and/or the Sponsor’s representatives, and promptly providing 
requested follow-up information regarding SAEs is essential so that ethical and regulatory responsibilities and 
legal obligations can be satisfied .  Investigators are responsible for reporting SAEs according to the following 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 49 of 111  
 
timeframes:  
 
• All SAEs occurring during the study should be reported immediately. 
• The SAE Report Form and relevant source documents, if applicable, must be completed and emailed 
to [EMAIL_2477]  within 24 hours of observation or learning of the event.  
• Follow- up information must be sent to the CRO within [ADDRESS_210793] to follow  up. 
 
[IP_ADDRESS] SAE Information to Report  
 All information available regarding an SAE must be submitted in the timeframes indicated .  At a minimum, 
SAE reports must cont ain the subject ID, the SAE  verbatim term, onset date, re lationship to study 
drug/causality, and a brief narrative of the event.  Please note that relationship to study drug/causality as 
well as the reported verbatim term are very important  and should be included in the initial report as it 
may impact expedited regulatory reporting requirements for the event.  The date of SAE discovery by [CONTACT_124537].  
 
The investigator must record all relevant information regarding an AE/SAE in the applicable sections of the 
CRF.  It is not acceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical records in lieu of 
completion of the appropriate AE/SAE pages.  However, there may be i nstances when copi[INVESTIGATOR_124497]/or the Sponsor.  If medical records are submitted to the CRO then all subject personal identifiers must be completely and thoroughly redacted prior to submission.  
A bla nk SAE Report Form and instructions for SAE reporting will be provided to the site and will be 
maintained in the investigator’s study file.  The SAE Report Form must be completed and emailed to [EMAIL_2477]  according to the timeframes specified in Section [IP_ADDRESS].  The SAE Report 
Form should include copi[INVESTIGATOR_124498], if applicable.  R econciliation of any discrepancy 
noted during monitoring and amending the eCRF is required.  
If new information about an SAE is received  or corrections to data are needed , the investigator should 
complete a new SAE Report Form and check the “follow-up” box on the form.  This follow-up SAE Report Form should be submitted within 24 hours of learning of the information, especially if the new information concerns seriousness, relatedness, or the event term of an AE.  
 Sites acting under their local IRB/IEC  should submit all applicable events, unanticipated problems, and safety 
reports to the site’s local IRB/IEC , if applicable.  All safety reporting deviations should also be submitted to 
their local IRB/IEC , if applicable.  
 
8.4.[ADDRESS_210794]  (AESI ), the event should meet the 
definition of an Adverse Event per Section 8.1.1. Thus, if the investigator considers the event to be an AE, and it meets one or more of the criteria listed below , then the event should be classified  as an AESI and 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210795]  (AESI)  if they qualify as AEs per the preceding 
paragraph :  
• Clinically  significant  peripheral edema or pulmonary edema . 
• Clinically significant systolic BP  >160  but <170 mmHg over consecutive timepoints spanning 30 or 
more  minutes.  
• Clinically significant systolic BP <90 or >170 mmHg at a single timepoint.  
• Clinically significant diastolic BP >100 but <110 mmHg over consecutive timepoints spanning 30 or 
more  minu tes. 
• Clinically significant diastolic BP <60 or >110 at a single timepoint.  
• A change of >25% from  baseline in systolic and/ or diastolic BP . 
• Reduced kidney function (eGFR < 45 mL/min/1.73 m
2). 
• Suspected transmission of blood- borne infectious agents.  
 
AESI occurring during the study should be reported within [ADDRESS_210796] be reported according to the timeframes specified in Section [IP_ADDRESS].  
 Note : Blood pressu res meeting the parameters above that are not considered adverse events need not be 
reported within the 48-hour window. Rather, these will be considered “blood pressures of special interest” 
and analyzed separately.  
 
8.4.[ADDRESS_210797]’s 
last dose in the event of early termination.   All pregnancies will be reported to the IRB/IEC , Sponsor, and 
CRO.  In the event of a pregnancy, treatment will be discontinued, and the subject will undergo continued 
safety follow -up through pregnancy outcome. 
 Any pregnancy must be followed by [CONTACT_179130].  Any 
anomalies, complications, abnormal outcomes, or birth defect (s) observed in the child must be reported as an 
SAE within 24 hours of the investigator or study personnel’s first know ledge. 
 
8.5 STUDY HALTING RULES  
 If any of the following safety events occur, a Safety Evaluation Meeting (defined below) will be triggered: 
• Three or more SAEs in the same SOC that are assessed as possibly or definitely related to the study agent 
by [CONTACT_167073] (see Section 8.2.2 Relationship to Study Agent ). 
• Within or between any of the dosing groups: an overall pattern of sym ptomatic, clinical, or laboratory 
events associated with the study agent that the Sponsor’s Program Physician or designee consider a 
serious potential safety concern  (e.g., suspi[INVESTIGATOR_179095]) . 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 52 of 111  
 
 
• Monitoring for this study will be performed by [CONTACT_941] s tudy CRO  in accordance with the Clinical Monitoring 
Plan (CMP) . 
• A mix of on- site and centralized m onitoring will be performed to e nsure the safety of clinical subjects and 
the accuracy and completeness of study data .  
• The Sponsor will be provided with copi[INVESTIGATOR_179096] r eports per the timelines specified within the 
CMP . 
• Details of clinical site monitoring tasks and scope are documented in the study’s CMP.  The CMP describes in detail who will conduct monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring  reports.  
• Independent audits may be conducted by [CONTACT_19489] a q uality oversight p lan or 
equivalent to ensure monitoring practices are performed consistently across all participating sites and that 
monitors are following the CMP. 
 
10 STATISTICAL CONSIDERATIONS 
10.1 STATISTICAL DESIGN MODEL  AND ANALYTICAL PLANS  
 
A Statistical Analysis Plan (SAP) with analytical details and assumptions will be developed and finalized before  
database lock and unblinding of the study data. 
 
10.[ADDRESS_210798] secondary efficacy  endpoints will be primarily descriptive; within -subject changes from basel ine for each 
dosing group and among-group differences will be evaluated.   
 
10.3 ANALYSIS DATASE TS 
 
Four analysis datasets are possible ; however, analyses may not necessarily be conducted with all four: 
• Intention -to-Treat (ITT) Dataset: all randomized  subjects. 
• Safety Dataset : all subjects who received a ny amount of the study agent.   
• Evaluable Dataset:  all subjects who receive at least [ADDRESS_210799] a diagnosis 
of PD and cognitive impairment per the inclusion criteria, and complete through Visit 8.  
– Per Protocol Dataset:  a subset of the Evaluable Dataset . A detailed description of the 
reasons for exclusion from the P er Protocol population will be included in the 
Statistical Analysis Plan (SAP) . 
 
The presentation of baseline characteristics will be conducted on the ITT dataset.  All safety analyses will be 
performed for the Safety Dataset.  Analyses  of the secondary endpoints will focus on the Evaluable and/or Per 
Protocol Datasets.  
 
 
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 53 of 111  
 
10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1 GENERAL APPROACH  
 
Using the Evaluable and/or Per Protocol Datasets, all secondary endpoints will be summarized serially 
over time using descriptive statistics to assess the within -subject changes and between -group 
differences.  Overall baseline and demographic data will be summarized using descriptive statistics; 
between -groups testing will be used to evaluate the effectiveness of the randomization in producing 
homogeneous pre- treatment groups.   
 For analysis of the primary and secondary endpoints, the following will be considered:  
• For endpoints that are continuous in nature: – Number of observations, mean, median, minimum and maximum, and standard deviation (SD) 
values will be presented as descriptive summary  
– For inferential statistics:  
 If the Normality assumption is met, Paired t -test, or Analysis of Covariance ( ANCOVA) using 
the baseline value as a covariate will be used  
 If the Normality assumption is not met, a rank –ANCOVA analysis i.e., an ANCOVA analysis on 
rank-transformed data or other non -parametric methods will be used  
• For endpoints that are categorical in nature:  
– Frequency counts and percentages will be presented as descriptive summary  
– Chi-square test or Logit model will be used for inferential statistics  
 
Subject disposition (e.g., the number of subjects randomized, completed, and discontinued) will be 
summarized , and medical history data will be listed.  Prior and concomitant medications taken from 
screening and during the study will be categorized by [CONTACT_167075], listed and summarized by [CONTACT_11840].   
 
Final analyses are not limited to the summaries described herein.  As noted above, analytical details 
and assumptions will be fully presented in the SAP. 
 
10.4.[ADDRESS_210800] attribution to the study agent.  
 
The AE analyses will focus on those that are T reatment -Emergent, however any AEs that are reported after 
consent has been signed and prior to initial dosing will be tabulated as Intercurrent Events. 
 
Additional details are presented in  Section 10.4.4.   
 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210801] significant changes in cognition, motor function , activities of daily living , 
etc.; however, using available data from analysis of the secondary efficacy  endpoints, including changes in 
scores from baseline, descriptive summari es will be developed.  Of particular interest will be the within -
subject changes from baseline and their distribut ion around a null value of zero and a comparison between  
groups to evaluate any trends in difference s between  subjects randomized to  active and placebo  agents .  
Appropriate paired sample tests (paired t -test or Wilcoxon Signed Rank tests) may be conducted to evaluate 
within -subject changes from baseline, using a two- tailed α -level of 0.05.  Between -group differences may be 
assessed by [CONTACT_179131]- way ANCOVA or its nonparametric equivalent test.  
 
10.4.4 ANALYSIS OF THE SECONDARY SAFETY ENDPOINTS  
 
Actual  values  and changes from baseline in clinical laboratory measurements, vital signs , body weight, and S-
STS scores  will also be assessed and summarized.  Abnormal  lab or vital sign  values will be determined and 
flagged in the listings.  Laboratory shift tables or graphics displaying the change (number of subjects) relative to the reference range from baseline to each study visit may also be presented for each test.  The investigator 
should exercise his or her medical and scientific judgment in deciding and document ing whether an abnormal 
laboratory finding, or other abnormal assessment is clinically significant.  
 For secondary safety endpoints that are continuous in nature (e.g. clinical laboratory parameters, systolic and 
diastolic BP , heart rate, respi[INVESTIGATOR_697],  body temperature, body weight, S -STS score) the mean, median, 
minimum, maximum , and standard deviation will be plotted over time. 
 For secondary safety endpoints that are categorical in nature (e.g. physical exam or ECG abnormalities), the 
frequency count s and percentages will be presented as a descriptive summary.  
 Per-subject extent of exposure will be listed.  
 
10.4.[ADDRESS_210802] series.  Reasons for study discontinuation will be compared across groups and across 
other subgroups of subjects, as appropriate.  
 
10.4.6 BASELINE DESCRIPTIVE STATISTICS  
 
See Section 10.4.1. 
 
10.4.7 PLANNED INTERIM  ANALYSES  
 
An unblinded interim analysis of the safety endpoints , including the primary endpoint and secondary safety 
endpoints, was conducted when approximately 20 subjects completed Visit 8 (end of first dosing period).   The requirement that subjects remain on an inpatient unit during each treatment  period was included in the 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210803] completed Visit 8 (end of first dosing period).  As the study is not powered for efficacy and no decisions will be made regarding stoppi[INVESTIGATOR_21356], statistical testing will be performed at the 0.05 level using two-tailed tests on both the Evaluable and Per Protocol datasets.  To 
minimize potential bias of the remaining efficacy and safety data, only aggregated summary tables will be 
provided.   
 
Safety will be monitored  on an ongoing basis.  If a Safety Evaluation Meeting is triggered (see Section 8.5), 
an ad hoc interim safety analysis will be performed.  If such an ad hoc safety interim analysis is conducted, the treatment assignme nt will remain masked , unless unblinding is deemed necessary by [CONTACT_179132].   
 
10.4.8 ADDITIONAL SUBGROUP  ANALYSES  
 
Not applicable.  
 
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY  
 
No adjustments for multiplicity will be employed.  
 
10.4.10 TABULATION OF INDIVIDUAL RESPONSE DATA  
 
This will be further defined in the SAP. 
 
10.4.11 EXPLORATORY ANALYSES  
 
Not applicable.  
 
10.5 SAMPLE SIZE  
 
A total of approximately 90 subjects will be randomized  in a 2:1 ratio to  active treatment  (approximately 60 
subjects) or  placebo (approximately 30  subjects ), with the intent of obtaining ~[ADDRESS_210804] differences in  measures of clinical  efficacy  or biomarker 
endpoints.  To evaluate potential safety signals , the statistical approximation described by [CONTACT_179133] (aka the “Rule 
of Threes” i n which the upper bound of the 95% confidence interval for the frequency  of an unreported AE is at 
most 3/n % where n represents the number of subjects who received active GRF6021 in the study) will be used.  
In a sample of 60  subjects, the upper  bound of the 95% confidence interval for the frequency of an unobserved 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 56 of 111  
 
AE is approximately 5%.  In addition, the proposed sample size may be sufficient to identify trends in efficacy 
endpoints that will be used to determine the appropriate sample size for subseque nt studies . 
 
10.6 MEASURES TO MINIMIZE BIAS  
 
10.6.1 ENROLLMENT/RANDOMIZATION/MASKING PROCEDURES  
 
To minimize the potential bias at the time of randomization, the study will be double -blinded and randomized 
in a 2:1 ratio (active:  placebo), with a mixed block size.  In addition to mixed block size, to reduce the 
potential impact of sex on study outcomes, the randomization will be stratified by [CONTACT_4321]; this is to assure a 
balanced distribution of evaluable male and female subjects in both treatment grou ps.  The randomization will 
be web -based and centralized.  The randomization codes will be generated by a statistician that has no 
involvement in the study other than generation and maintenance of the randomization codes.  
 
All study outcome measures will be assessed by [CONTACT_179134].  
However, vials containing  of the study agent or vials  containing placebo will be provided by [CONTACT_126531], or other qualified staff responsible  for drug accountability, to an unblinded Infusion 
Nurse  who will administer  the study agent or placebo.  To ensure that Outcomes Assessors, raters , and other 
study personnel, a s well as  subjects and trial partners are unaware of the allocation , appropriat e measures will 
be taken to mask the study agent /placebo containers and IV setup  such that they will only be visible as 
necessary to the unblinded Infusion Nurse.  These measures include, but are not limited to,  covering the vial 
and drip chamber with an opaque black bag or equivalent; using a curtain, drape, or equivalent to shield the infusion administration setup  as applicable; concealing  vials/containers  of study agent/placebo during 
transport;  and returning used containers of the study agent /placebo  to the unblinded pharmacist, or other 
qualified site personnel responsible for drug accountability, promptly at the end of the Infusion Period.   
 Communication between the blinded Outcomes Assessor and the  unblinded Infusion Nurse will be restricted 
to only that required to ensure the immediate safety of subjects.  The Outcomes Assessor will observe the 
subject during the infusion and collect and/or manage/report AEs and SAEs.    
Finally, to avoid potential unblinding based on subject  levels,  lab results (aside from 
those tested at screening) will remain blinded until the conclusion of the study.  Unblinding of  
lab results would only occur for emergent safety reasons. 
 Aside from de signated personnel whose sole responsibility necessitates access to unblinding information 
(e.g., the unblinded CRA whose sole responsibility is to ensure study agent/placebo accountability, the unblinded clinical supply manager, etc.) , the Sponsor and the ir representatives will be blinded with respect to 
subjects’ treatment allocation  through database lock unless breaking the blind is required for safety reasons 
(see 10.6.3 Breaking the Study Blind/Subject Code ).  The unblinded interim analys es will be performed by 
[CONTACT_179135]. The data will be provided in 
aggregate fashion so the difference between study agent and placebo is compared b ut individual treatment 
allocation remains blinded.  
  
 

 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 57 of 111  
 
10.6.2 EVALUATION OF SUCCESS OF BLINDING  
 Success of blinding will be assessed based on all occurrences (intentional or unintentional) of unblinding of blinded study subjects, their trial partners, or study personnel (e.g. investigators, medical providers, 
cognitive /motor  testing raters, the Sponsor or their representatives).  All intentional and unintentional 
unblinding will be documented and reported.   
 
10.6.3 BREAKING THE STUDY BLIND/SUBJECT CODE  
 
The study blind can  be broken for safety reasons if the information is required for the management of SAEs or 
severe AEs.  Only the Investigator can obtain the treatment allocation for their subject through the IRT.  
Before breaking the blind, every attempt should be made to discuss the need with the Sponsor ’s Program 
Physician, or designee .  When some degree of unblinding must occur, this should be limited to the fewest 
number of people on a need- to-know basis.   
 
Any noted intentional or unintentional breaking of the blind should be documented and reported to the 
Sponsor’s Study Team Lead.   If unintentional unblinding occurs during t he study, root cause analysis will be 
evaluated, and corrective actions implemented.  
 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS 
 
Each participating site will maintain appropriate medical and research records for this trial, in compliance with  
ICH E6 R2 and regulatory and institutional requirements for the protection of confidentiality of subjects.  Each site 
will permit authorized representatives of regulatory agencies, the IRB/IEC , the Sponsor, or the Sponsor’s 
representatives to examine (and  when permitted by [CONTACT_1289], to copy) clinical records for the purposes of 
quality assurance reviews, audits, and evaluation of the study safety, progress, and data validity.    
Source data are all information, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory not es, memo randa , 
subject’s memory aids or evaluation checklists, pharmacy dispensing records, recorded audio tapes of counseling sessions, recorded data from automated instruments, copi[INVESTIGATOR_167044], microfiches, photographic negatives, microfilm or magnetic media, x -rays, and subject  files 
and records kept at the pharmacy, at the laboratories, and medico- technical departments involved in the clinical 
trial.   
 It is not acceptable for the CRF to be the only record of a subject’s participation in the study.  This is to ensure that 
anyone who would access the subject’s medical record has adequate knowledge that the subject is participating in a 
clinical trial.  Source document templates will be developed for this study.  
 
12 ETHICS/PROTECTION OF HUMAN SUBJECTS 
12.[ADDRESS_210805] 
 
The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, ICH E6 R2, 21 CFR, 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page [ADDRESS_210806]/ ETHICS COMMITTEE  
 
This protocol and any accompanying material to be provided to the subject (such as advertisements, subject information sheets, or descriptions of the study used to obtain informed consent) will be submitted by [CONTACT_179136].  Approval from the IRB/IEC  must be obtained before starting the study and should 
be documented in a letter to the investigator specifying the protocol number, protocol version, documents 
reviewed, and date on which the committee met and granted the approval.  
 
All changes to the consent form will be IRB/IEC  approved; a determination will be made regarding whether 
previously consented subjects need to be re- consented.  
 Any modifications or amendments to the protocol must also be submitted to the IRB/IEC  for approval prior to 
implementation.  
 
12.[ADDRESS_210807] utilize an IRB/IEC -approved consent form that contains the elements 
required by [CONTACT_179137] e regulatory requirements for documenting written informed consent.  
Each informed consent will be appropriately signed and dated by [CONTACT_3184]/or their legally authorized 
representative and the person obtaining consent.  A copy of the signed consent form will be provided to the subject and/or their legally authorized representative.  By [CONTACT_1725], all parties agree 
they will complete the evaluations required by [CONTACT_1758], unless they withdraw voluntarily or are terminated 
from the study for any reason. 
 
Investigators will be expected to maintain a screening log of all potential study candidates that includes 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 59 of 111  
 
limited information about the potential candidate (e.g., date of screening).   
All subjects who provide consent will be assigned a unique study number.  This number will be used to 
identify the subject throughout the clinical study and must be used on all study documentation related to the study subject.  Once a number is assigned to a subject, that number will remain with th at study subject and 
will not be reused.  
 
If an individual’s medical chart or results of diagnostic tests performed as part of an individual’s regular medical  care are going to be used for screening,  written informed  consent must  be obtained  prior  to review  
of that information in accordance with the Health Insurance Portability and Accountability Act ( HIPAA )
. 
 
12.[ADDRESS_210808] party without prior written approval of the Sponsor.  
The study monitor, other authorized representatives of the Sponsor , representatives of the IRB/IEC , or 
government regulatory agencies  may inspect documents and records required to be maintained by [CONTACT_093], 
including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the subject s in 
this study.  The clinical study site will permit access to such records.  
 The study subject ’s contact [CONTACT_179138].  At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_15686]/IEC  and Institutional regulations.   Study subject s’ research data, which is for purposes of 
statistical analysis and scientific reporting, that is  transmitted to the Sponsor, CRO, and/or IRB/IEC  will not 
include contact [CONTACT_1290].  Rather, individual subjects and their research data will be identified by a unique study number.  This unique study number  should be recorded on non- local lab samples, requisitions, 
and any documents submitted to the CRO, Sponsor,  and/or IRB/IEC .  The s tudy data entry and study management 
systems used by [CONTACT_64496].  
 
12.[ADDRESS_210809] ’s (or the subject’s legally authorized representative’s)  approval and as approved by [CONTACT_179139]/IEC s, biological samples may be stored at Alkahest , or designee, for future use .  These samples could be 
used for research and to improve treatment.  Alkahest will also be provided with a code- link that will allow 
linking the biolog ical specimens with the specific data from each subject , maintaining the masking of the identity 
of the study subject .  Subjects may choose whether the Sponsor can store and use samples for further research .  
 
An individual subject can choose to withdraw consent to have biological specimens stored for future research.  
Samples from subject s who  provide consent for future research purposes  are collected , stored , and code-linked to 
the subject until the end of the study at which time t he samples are deidentified and may no longer be connected 
to the individual subject.  Throughout the study, at any time , the subjec t and/or the subject’s LAR is able to 
withdraw consent , and the individual samples can be retrieved and destroyed .  Howev er, after the samples have 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 60 of 111  
 
been deidentified , this may not be possible. 
 
When the study is completed, access to study data and/or samples will be managed by [CONTACT_124546].  In the event 
Alkahest transfers ownership to another commercial Sponsor , ownership of the samples may be transferred as 
well.  
[ADDRESS_210810]  and substantiate the integrity of the data 
collected.  Source documents are filed at the investigator’s site.   Data entered in the eCRFs that are transcribed 
from source documents must be consistent with the source documents or the discrepancies must be explained.  All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Black 
or blue ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014].  When making changes or corrections, cross out the 
original entry with a single line, and initial and date the change.  DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.   The investigator may need  to request previous medical 
records or tran sfer records, depending on the trial; also , current  medical records must be available.  
 
For each subject  enrolled in the study, the  eCRF must be completed in a timely manner.  The investigator will 
review and approve  the e CRF f or each study subject after all data have been entered, the e CRFs have been source 
document verified, and all queries have been resolved. This als o applies to records for those s ubjects who fai l to 
complete the study.  If a subject withdraws from the study, the reason must be noted on the e CRF.  If a subject is 
withdrawn from the study because of an AE, thorough efforts should be made to clearly document the outcome. 
 All data collection and recordkeepi[INVESTIGATOR_179097]. 
 
13.1.1 INVESTIGATOR RESPONS IBILITIES  
 
The investigator will comply with the protocol (which has been approved/given favorable opi[INVESTIGATOR_179098]/IEC ), ICH GCP, and applicable regulatory requirements.  The investigator is ultimatel y responsible for 
the conduct of all aspects of the study at the study site and verifies by [CONTACT_179140].  The term “investigator” as used in this protocol as well as in other study 
documents, refers to the  investigator or authorized study personnel that the investigator has designated to 
perform certain duties.  Sub -investigators or other authorized study personnel are eligible to sign for the 
investigator, except where the investigator’s signature [CONTACT_1788]. 
 
13.1.[ADDRESS_210811] of the study to be fully documented and the study data to be subsequently verified.  These documents should be classified into two 
separate categories (although not limited to) the following: (1) investigator’s study file, and (2) subject 
clinical source documents.  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 61 of 111  
 
 The investigator’s study file will contain the protocol/amendments, e CRF, IRB/IEC  approval with 
correspondence, informed consents , drug records, staff curriculum vitae and authorization forms, and other 
appropriate documents and study- specific manuals (e.g., lab m anual) . 
 
Subject clinical source documents would include (although are not limited to) the following: subject 
hospi[INVESTIGATOR_307]/clinic records, physician’s and nurse’s notes, appointment book, original laboratory reports, ECG, 
radiologic imaging, X- ray, pathology and specia l assessment reports, consultant letters, screening and 
enrollment log, etc. 
 
13.[ADDRESS_210812] been notified.  Before the investigator destroys any material related to the clinical 
study, he/she must obtain approval in writing from the Sponsor. 
 
The investigator should keep a file where the full name [CONTACT_179144] [ADDRESS_210813] , the investigator, or the study site staff.  When deviations occur , corrective 
actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
 
Protocol Deviations will be categorized as either M ajor or M inor and will be defined in the study- specific 
Protoc ol Deviation Plan.   
 
Major Protocol Deviation : a departure from the approved protocol relating to the conduct of the study which 
may significantly impact the completeness, accuracy, and/or reliability of the study data or that may significantly 
affect the rights, safety or wellbeing of study participant s. 
Examples of Major Protocol Deviations include, but are not limited to:  
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 62 of 111  
 
• Failure to obtain informed consent (i.e., no evidence of informed consent)  
• Enrolling subjects in violatio n of key eligibility criteria designed to ensure a specific subject populatio n 
• A drug dispensing or dosing error that could have affected the safety of the subject  
• Failing to collect data necessary to interpret primary endpoints, as this may compromise the scientific value of the trial 
Major Protocol Deviations may result in data that are not deemed evaluable for the per protocol analysis and/or 
may require that subjects are discontinued from the study.   Observations categorized as Major may include those 
situations where there is a patt ern of  deviation, numerous Minor observations, or other significant deviation. 
 
Minor Protocol Deviation : a departure from the approved protocol relating to the conduct of a study that does 
not affect the rights, safety, and/or wellbeing of study participants or the study outcomes or data quality.  
Examples of Minor Protocol Deviations include, but are not limited to: 
• A protocol visit date outside of a visit window 
• An isolated case of a missed or incomplete study procedure (e.g., laboratory test)  
• An isolated incident of a missed or incomplete study evaluation (e.g., examination) 
Minor Protocol deviations would not gen erally preclude subject data from the per protoco l analysis population. 
Observations categorized as Minor may become Major if not corrected. 
 
 
All deviations will be logged and tracked by [CONTACT_167079].  Periodic review of Protocol Deviations will serve 
an indicator  of site performance.  
 It is the responsibility of the site to use continuous vigilance to identify and report deviations promptly to the study CRO and/or Sponsor.  All deviations must be addressed in study source documents.  Notification of 
Protocol D eviations must be sent to t he local IRB/IEC  per their guidelines.  The site PI/study staff are  responsible 
for knowing and adhering to their IRB/IEC  requirements.  
 
13.4 PUBLICATION AND DATA SHARING POLICY 
 
In compliance with The International Committee of Medical Journal Editors ( ICMJE) clinical trials registration 
policy and Section [ADDRESS_210814] of 2007, this study will be registered by [CONTACT_124548].gov, a public trials registry which is sponsored by [CONTACT_10418].  
 Notwithstanding the Sponsor’s requirements for registration and data sharing in ClinicalTrials.gov, any formal 
presentation or publication of data collected as a direct or indirect result of this trial will be considered as a joint 
publication by [CONTACT_093](s) and the Sponsor.  In the case of multicenter studies, it is mandatory that the first publication be made based on the totality of data obtained from all centers, analyzed as stipulated in the protocol, 
and presented and interpreted as documented in the final Clinical Study Report.  The resulting publication will 
name [CONTACT_179145].  Where it is not permitted for all investigators to 
be included as authors, the publication will name [CONTACT_179146]. 
 
Individual investigators may publish data arising from their own subjects.  The investigator will provide the 
Sponsor with copi[INVESTIGATOR_124504] (including abstracts and posters) at least 60 days in advance of 
submission.  This review is to permit the Sponsor to review the communication for accuracy (thus avoiding 
potential discrepancies with submissions to regulatory authorities), to verify that confidential information is not 
 
Protocol ALK6021 -201   V5.0 23SEP2019 
 
_________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                  Page 63 of 111  
 
inadvertently divulged (including patent protection), to allow adequate input or supplementary information that may not have been available to the investigator, and to allow establishment of co-authorship. 
 
Investigators participating in multicenter studies must agree not to engage in pres entations based on data gathered 
individually or by a subgroup of centers before publication of the first main publication unless this has been 
agreed otherwise by [CONTACT_124549].  However, in the event that no publication of the 
overall results has been submitted after approval of the Clinical Study Report, investigators may publish results of 
one or more center’s subjects to the same review as outlined above.  The Sponsor will circulate proposed 
multicenter publications to all inv estigators for review.  
 
Data will be reviewed by [CONTACT_106126].  The study Sponsor will have [ADDRESS_210815] and will establish a 
mechanism for their  management.  
 
 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 69 of 111  
 
 
and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. December, 2012. 
 Gahart BL, Nazareno AR, Ortega MQ.   Gahart’s 2019 Intravenous Medications: A 
Handbook for Nurses and Health Professionals.  Elsevier, St. Louis, Missouri, 2019.  
 
Gebhard C, Stahli B, Jenni R, Tanner FC.  Effect of age on left ventricular ejection fraction assessed by 
[CONTACT_51541].  Eur Heart J. 2012;33:1. 
 
Goldman JG, Litvan I.  Mild cognitive impairment in Parkinson’s Disease.  Minerva Med. 2011;102:441-459.   
Janvin CC, Larsen JP, Aarsland D, Hugdahl K .  Subtypes of mild cognitive impairment in Parkinson’s disease: 
progression to dementia.  Mov Disord. 2006;21:1343-1349.  
Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al.  MDS Task Force on mild cognitive impairment in Pa rkinson’s disease: critical review of PD -MCI.  Mov Disord. 2011;26:1814-1824. 
 Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Peterson RC, et al.  Diagnostic criteria for mild 
cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines.  Mov Disord. 
2012;27:349-356.  
Martinez-Martin P, Forjaz MJ, Cubo E, Frades B, de Pedro Cuesta J, ELEP Project Members.  Global versus 
factor -related impression of severity in Parkinson’s disease: a new clinimetric index (CISI -PD). Mov Disord. 
2006;21:208-214.  Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease.  The Unified Parkinson’s 
Disease Rating Scale (UPDRS): status and recommendat ions.  Mov Disord. 2003;18:738-750. 
 Müller S, Preische O, Heymann P, Elbing U, Laske C.  Increased diagnostic accuracy of digital vs. conventional 
clock drawing test for discrimination of patients in the early course of Alzheimer’s disease from cognitively 
healthy individuals.  Front Aging Neurosci. 2017; 9:101.  
 Nasreddin e ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al.  The Montreal Cognitive 
Assessment, MoCA: a brief screening tool for mild cognitive impairment.  Am Geriatr Soc.  2005;53:695-699.  
Olanow CW, Stern MB, Sethi K.  The scientific and clinical basis for the treatment of Parkinson disease (2009).  
Neurology. 2009;72(Suppl 4) S2-S136. 
 
Parkinson J.  Essay on the Shaking Palsy.  Monograph.  London: Whittingham and Rowland for Sherwood, Neely 
and Jones, 1817. 
 
Peto V, Jenkinson C, Fitzpatrick R.  PDQ-30: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures.  J Neurol. 1998;245[Suppl1]:S10-
S14. 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 70 of 111  
 
 
 
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al.  MDS clinical diagnostic criteria for 
Parkinson’s disease.  Mov Disord. 2015;30:1591-1588.  
 USP.  June , 2018. 
 
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A.  Pathological verification of ischemic score in 
differentiation of dementia. Arch Neurology. 1980;7:486-488. 
 
Savica R, Grossardt BR, Rocca WA, Bower JH .  Parkinson disease with and without dementia: a preval ence study 
and future projections.  Mov Disord. 2018: Jan 22 [Epub ahead of print].     
Schneider JS, Sendek S, Yang C.  Relationship between motor symptoms, cognition, and demographic 
characteristics in treated mild/moderate Parkinson’s disease.  PLos ONE. 2015;10(4):e0123231. 
 
Schwab RS,  England  AC.  Parkinson syndrome due to various and specific causes.  In: Vinkin PJ, Bruyn, eds. 
Handbook of Clinical Neurology .  Amsterdam: Elsevier North Holland. 1968: 227-247. 
 Sheehan DV, Giddens JM, Sheehan IS.  Sheehan -Suicidality Tracking Scale (S- STS) 2014.  Innov Clin Neurosci. 
2014;11(9-10)93-140. 
 
Svenningsson P, Westman E, Ballard C, Aarsland D.  Cognitive impairment in patients with Parkinson’s disease: 
diagnosis, biomarkers, and treatment.  Lancet Neurol. 2012; 11:697 -707. 
 Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al.  The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90-94. 
 
Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al.  Young blood reverses age-
related impairments in cognitive function and synaptic plasticity in mice.  Nat Med. 2014 Jun;20(6):659-663. 
 
Wesnes K.  Clinical trials in which the CDR system has been employed to detect enhancements in cognitive 
function.  Poster presentation at the International Conference of Science and Technology Management (ICSTM) 
Annual Scientific Meeting, February, 2013, Washington, D.C. 
 
Wesnes K.  The effects of psychotropic drugs upon human behavior.  Mod Probl Pharmacopsych.  1977;12:37-58.  
Wesnes K.  The value of assessing cognitive function in drug development.  Dialogues Clin Neurosci. 
2000;2:183-202. 
 Yesavage JA, Brink TL, Rose TL, Lum O, Huang W, Adey MB, et al.  Development and validation of a geriatric 
depression screening s cale: A preliminary r eport. J Psych Res. 1983;17:37-49. 
 
 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 71 of 111  
 
 
16.2 UNPUBLISHED REFERENCES  
 
2018- CET -01.  Actual e ffects of  on neuronal activation in aged wild type 
mice . 
 
2018- CRL03 .  Effects of  in the MPTP mouse model of Parkinson’s disease.  
 
2018- QPS01 .  Effects of  in line 61 mice. 
 ALK-2015-R002.  Effects of young and old human plasma on cognition in NODscid mice. 
 
   April, 2018. 
 
VIV-2016-R003.  Effects of young human plasma  on neurogenesis, 
inflammation and cognition. 
 VIV-2016-R009.  Effects of  on cognition, behavior and histopathological 
endpoints in aged NSG mice.  VIV-2016-R014.  Young plasma and  effects on behavior and survival in 
aging NODScid mice.  
 
VIV-2016-R020.  Effects of  on cognition. 
 
VIV-2016-R021.  Effects of young and aged human plasma and  on 
histopathological endpoints in aged NSG mice.  
VIV-2016-R024.  Effects of human plasma and  on cognition, behavior and 
histopathologic endpoints in aged NSG mice. 
 VIV-2017-R025.  Effects of  on c ognition in a ged NSG m ice (2).  
 VIV-2017-R036.  Effects of  on histopathological endpoints in aged NSG  
mice.  
 VIV-2017-R038.  Effects of  on cognition, behavior and histopathological 
endpoints in aged C57BL/6J mice. 
 VIV-2018-R069.  Effects of  on cognition and neurogenesis in aged, 
C57BL/6J mice.  
 
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 72 of 111  
 
 
17 APPENDICES 
 Appendix 1.  Montreal Cognitive Assessment  
The MoCA ( Nasreddine 2005) is a commonly used screening test easily administered by [CONTACT_179121].  It 
assesses the domains of attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.  The total possible sco re is 30 points with a score of 26 or 
more considered normal. For additional informatio n, the  assessment  can be downloaded using the following link: 
Montreal Cognitive Assessment (V7.1).  
 
 
 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 73 of 111  
 
 
Appendix 2.  Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale  
The MDS -UPDRS ( Fahn 1987, Movement Disorder Society Task Force 2003) was developed as an effort to 
incorporate elements from existing scales to provide a comprehensive but efficient  and flexible means to monitor 
PD-related disability and impairment.  The MDS -UPDRS has four components (Part 1, Mentation, Behavior, and 
Mood; Part 2, Activities of Daily Living; Part 3, Motor; Part IV, Complications).  For the current study, only Parts  
1, 2, 3 and total score will be utilized.  The rating for each item is from 0 (normal) to 4 (severe).  The total score for 
each Part is obtai ned from the sum of the corresponding item scores.  The estimated time for completion of Parts 1-
3 is 20 -30 minutes. For additional information, the full assessment  can be downloaded using the following link: 
MDS -UPDRS . 
 
 
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 74 of 111  
 
 
Appendix 3.  Schwab and England  Activitie s of Daily Living  
The SE-ADL evaluates patients’ perception of global functional capacity and dependence ( Schwab 1968 ).  Scoring 
is expressed in terms of percentage, in 10 steps from 100 to 0 (100%, normal status; 0%, bedridden with vegetative dysfunction), so that the lower the score, the worse the functional status. The rating is made by [CONTACT_179141]/professional. For additional information, the full assessment can be downloaded using the following l ink: 
Schwab and England Activities of Daily Living Scale .  
 
 
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 75 of 111  
 
 
Appendix 4.  Clinical Impression of Severity Index – Parkinson’s Disease  
The CISI -PD (V2)  is a severity index formed by [CONTACT_179123] (motor signs, disability, motor complications and 
cognitive status), rated 0 (not at all) to six (very severe or severely disabled). A total score is calculated by [CONTACT_179124].  The scale is completed by a clinician at the time of assessment.  It takes a few seconds 
to complete once the state of the patient is known ( Martinez-Martin 2006). For additional information, the full 
assessment can be downloaded using the following link: Clinical Impression of Severity  Index: Parkinson’s 
Disease (V2) . 
 
 
  
   

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 76 of 111  
 
 
Appendix 5.  Parkinson’s Disease Quality of Life Questionnaire -39 
The PDQ -39 is a self-administered questionnaire of 39 questions relating to 8 key areas of health and daily 
activities, including both motor and non- motor symptoms ( Peto 1998 ).  The eight dimensions include: mobility, 
activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily 
discomfort.  It is scored on a scale of 0 -100 with lower scores indicating better health and high scores indicating 
more severe symptoms.  For additional information, the full assessment can be downloaded using the following link: Parkinson’s Disease Quality of Life Questionnaire -39. 
 
 
 
 
 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page [ADDRESS_210816] week ( Yesavage 1983 ).  The GDS -S should be given orally. A 
clear YES or NO answer is required for each question. If necessary, repeat the question but do not accept a 
qualified answer from the test -taker.  Cross off either yes or no for each question. Depressive answers (errors) are 
circled on the form and are bolded below.  Count up 1 for each depressive answer (error).  The final score is the tally of the number of depressive answers with the following scores indicati ng depression:  0-4 No depression,  
5-10 Suggestive of a mild depression, and 11 + Suggestive of severe depression. For additional information, the 
full assessment can be downloaded using the following link: Geriatric Depression Scale-15.  
 
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 78 of 111  
 
 
Appendix 7. Sheehan Suicidality Tracking Scale  
The S- STS was developed to provide a brief but efficient instrument for use in assessing change in suicidal 
ideation and behavior while providing a comprehensive description of suicidal ideation and behavior ( Sheehan 
2014). The primary goals in the design of the S- STS were for the scale to be: 1) short and inexpensive; 2) s imple, 
clear, and eas y to administer or self -rate; 3) highly sensitive (i.e., able to detect a high proportion of patients who 
are suicidal); 4) s pecific (i.e., able to screen out those who are not suicidal); 5) sensitive to change in suicidal 
ideation and behavior; 6) compati ble with the regulatory categories of assessment for suicidal ideation and 
behavior; 7) useful in clinical as well as research settings; 8) useful in detecting an efficacy signal for anti-suicidal medications; and 9) c apable of use in pediatric and geriatric settings .  The standard version of the S -STS is a 16 -
item scale that assesses the seriousness of suicidality phenomena on a Likert -type scale (0 -4) ranging from “ not at 
all” (0) to “extremely” (4).  It also assesses the frequency of key phenomena and th e overall time spent in 
suicidality. For additional information, the full assessment can be downloaded using the following link: Sheehan Suicidality Tracking Scale.
   
   
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 79 of 111  
 
 
Appendix 8.  Movement Disorder Society’s Parkinson ’s Disease Criteria  
 
    
Provided for use in clinical trial documentation in Postuma 2015 . 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 80 of 111  
 
 
Appendix 9.  Criteria for Parki nson’s Disease with Mild Cognitive Impairment
Reprinted with permission from Litvan 2012 .   
  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 81 of 111  
 
 
Appendix 10.  Parkinson’s Disease with Dementia Criteria
 
Reprinted with permission from Emre 2007 . 
 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 83 of 111  
 
 
• An appropriately qualified blinded Outcomes Assessor will monitor the subject throughout the infusion and 
for approximately 4 hours after the infusion has been completed. This person’s qualifications must enable 
them to identify AEs , monitor vital signs , and take the appropriate course of action when an AE or clinically-
significant vital sign change occurs.  
• Sites must identify and follow procedures that ensure adequate blinding of blinded study personnel, subjects, and trial partners  before, during, and after the Infusion Period. This may include the use of study drug 
container covers and /or the use of drapes to separate the unblinded Infusion Nurse and infusion apparatus 
from the blinded Outcomes Assessor, PI, subject, and trial partner.     
• The unblinde d pharmacist, or other qualified site personnel responsible for drug accountability, must retain 
all used vials /containers  for drug accountability , unless otherwise agreed t o with the Sponsor .  These should 
be kept in a secure location with limited access to minimize the risk of unblinding blinded study staff.  
Partially -used vials /containers may not be re -used. 
4. INSTRUCTIONS FOR THE  UNBLINDED INFUSION NURSE  
4.1. Equipment and Supplies  
The following equipment and supplies will be needed for each infusion: 
 
Infusion Supplies (Provided by [CONTACT_2728]) 
• GRF6021 or p lacebo  
• Hangers for  IV vials  (for blinding) 
• Black IV Cover Bags  (for blinding)  
 
Infusion Supplies (Not provided)  
• Volumetric infusion pump 
• IV spi[INVESTIGATOR_179099] (vented)  
• Pump -compatible IV tubing (without inline filter)  
• IV Start Kit or equivalent supplies  
• 18-20 gauge peripheral IV catheter 
• Pi[INVESTIGATOR_179100] 
• 0.9% s aline for injection (50  mL bags or 10 mL syringes)  for post IV line or peripheral IV 
flush  
• Gloves  
• Alcohol pads 
• IV pole 
• Injectable cap and luer -lock connector (if applicable) 
• Epi[INVESTIGATOR_179101]/Epi [INVESTIGATOR_179102]   
• Heparin Lock and syringe (if used) 
• Sharps container  
• Privacy screen/blinding setup during infusion  
 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 84 of 111  
 
 
Gene ral Study Supplies                        
• Infusion source notes for the unblinded Infusion Nurse  
• Study Drug Infusion Rate Table (See Table 1. Study Drug Infusion Rates ) 
 
If the site is unable to source needed infusion supplies, the Sponsor will assist in provisioning the required 
materials.  
 
4.2. Blinding  
Each site is required to ensure an appropriate blinding setup is prepared before each infusion and must document the setup employed.  This may include any or all of the following: 
• A privacy screen (or similar) to shield subject, subject’s trial partner, and all blinded study 
personnel from the infusion setup  
• Opaque bag or similar, to mask the content of the glass vial /container  
• Other masking devices  
 
4.3. Prior to Infusion  
The unblinded Infusion Nurse will take care to ensure the appropriate blinding of the study d rug at all times.  
Prior to infusion:  
a. Verify subject identity.  
b. Verify randomization assignment/ kit number.   
c. Visually inspect the study drug vial  for particulate matter or cracks in the vial. Do not use the 
solution if the vial is cracked or if the solution contains discrete foreign particulate matter.  Do not shake.  Do not use if the vial  has been frozen. Study drug should be stored and infused at 
room temperature.  
d. Obtain the study drug vial  from the pharmacy and ensure that it is not visible when being 
transported to the infusion room  or while setting up the IV apparatus. 
e. Follow site procedures for peripheral IV catheter insertion, IV setup, and locking (if applicable). 
f. The study drug vial  should be spi[INVESTIGATOR_179103] 4 hours before infusion start. 
 
It is recommended to prime the line using the study drug (either GRF6021 or placebo), while being 
careful to limit the amount of study drug that is lost (no more than 2 -3 mL is ideal). The amount of 
study drug lost during priming should be noted in the infusion source record , without disclosing any 
information that could be potentially unblinding.  
 
4.3.1.  Considerations if Using a Heparin or Saline Lock  
If the peripheral IV site will be locked with saline or heparin, the following steps should be considered:  
• Locked peripheral IV sites should be assessed prior to and after each use to inspect for swelling, redness, pain, warmth, and phlebitis.  
 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page [ADDRESS_210817] your site’s unblinded CRA for further instruction.  
4.5. Post-Infusion  
a. Depending on your infusion line’s loading volume, sufficient saline should be used to flush the IV line 
to ensure  of study drug was infused into the subject.   
b. When the infusion is complete, flush the peripheral IV catheter as ordered if it will remain in place (see 
Section 4.3.1) or discontinue it as appropriate.  
c. The unblinded Infusion Nurse will document the following information on the subject’s infusion source 
record:     
• Subject ID 
• Date and time of infusion start and stop 
• Infusion vial label checked for accuracy; record unique vial ID number 
• Actual volume infused (if less than )  
• What infusion method or pump that was used 
• Titration steps (e.g. changes in flow rate and time of change) 
• Vascular access device and status (including all flushes)  
d. Following the infusion, the infusion source record should be maintained with the subject’s records.  
e. The unblinded Infusion Nurse should return the used vial  to the unblinded pharmacist, or other qualified 
personnel responsible for drug accountability. During transport, ensure the vial /container  is concealed 
from view.  
 
5. INSTRUCTIONS FOR THE  BLINDED OUTCOMES ASSESSOR AND INVESTIGATOR  
 
5.1. Equipment and Supplies  
The Outcomes Assessor will need the following equipment and supplies for each infusion:  
• Source notes for the blinded Outcomes Assessor  
• Sphygmomanometer, or equivalent device for measuring BP  and heart rate  
• Pulse oximeter (optional)  
• Thermometer  
• Body weight scale 
5.2. Prior to Infusion  
The blinded Outcomes Assessor will check the following information prior to infusion start: 
a. Subject identification to ensure it is the correct subject.  
b. Verify eligibility criteria (e.g. subject’s history and diagnosis, including allergies and previous 
reactions to blood or blood products). 
c. Review AEs and concomitant medications.  
d. Baseline vital signs (temperature, seated BP, orthostatic BP , heart rate, respi[INVESTIGATOR_697], and 
weight) within [ADDRESS_210818] data on source document. 

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 92 of 111  
 
 
5.4.2  Previously read:  Approximately 90 subjects 
(GRF6021: 60; placebo: 30) will be enrolled in the study with the intent of obtaining ~[ADDRESS_210819] 5 
doses and completed through Visit 8 . 
 
Now reads:  Approximately 90 subjects (GRF6021: 60; 
placebo: 30) will be enrolled in the study with the intent 
of obtaining ~68 evaluable subjects . 
 Additional detail not 
required in this section as 
it is detailed in Section 10 Statistical Considerations.  
6.1.2, 10.6.1  Clarified that saline placebo is supplied in  
 glass vials.  Revised for clarity.  
[IP_ADDRESS].8  Provided additional detail regarding assessment 
of motor function as part of the neurological 
exam.  Revised to clarify the 
motor function portion of the neurological exam.  
[IP_ADDRESS].8.2, 7.3.[ADDRESS_210820] Protocol Clarification 
Memorandum #2. Revised to provide 
additional clarity to sites using an i -STAT 
handheld device to assess 
pre-infusion safety labs.  
7.2.1  Removed sentence indicating total blood volume 
collected during the study. This information is 
conveyed in the Informed 
Consent Form and may 
vary depending on whether unscheduled labs 
are collected.  
7.3 Previously read:  Visit windows (when noted) 
should be benchmarked relative to Visit [ADDRESS_210821], such that subjects complete the entire 
study by [CONTACT_2006] 168 (± 7 days).  
 
Now reads:  To ensure follow -up visits occur at 
approximately the same intervals following both 
treatm ent periods, visit windows should be calculated 
as follows:  
 
• Visit windows for Visits 1 -10 should be 
calculated relative to Day 1.  
• Visit windows for Visits 11 -19 should be 
calculated relative to Day 85 ±7 (i.e., first day 
of dosing for Treatment Period 2).  Revised to  ensure follow -
up assessments are conducted at consistent 
intervals post -treatment.  

 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 93 of 111  
 
 
 
7.3.5  • Visit 16 day interval was changed from “90 + 
3 Day s” to “90 + 7 Days.” 
• Text added: “ Note: Visit 16 (Day 90) may be 
split to allow for sufficient time to complete 
all required procedures. Review AEs and 
concomitant medications during split visits, 
as applicable. ”  Revised to enhance  study  
feasibility.  
8.4.3  • Modified to reflect Protocol Clarification 
Memorandum #3. 
• The qualification of “Clinically significant” 
was added to measurements of systolic and 
diastolic blood pressure . 
• The following note was added: “ Note: Blood 
pressures meeting the parameters above that are not considered adverse events need not be 
reported within the 48-hour window. Rather, these will be considered “blood pressures of 
special interest” and analyzed separately. ” Revised to  provide clarity 
regarding Adverse Events 
of Special Interest and 
reporting requirements.  
10.3 • The safety dataset includes all subjects who 
received any amount of the study agent as 
opposed to “at least one dose.” 
  
  
• In the description of the evaluable dat aset, 
added the following text, “have a diagnosis 
of PD and cognitive impairment per the 
inclusion criteria” 
 Since the IMP is 
administered by [CONTACT_27650], subjects who 
receive any volume of 
IMP will be considered part of the safety dataset.  
 
Revised to ensure that 
only subjects who have a 
diagnosis of PD and 
cognitive impairment are 
included in the evaluable  
dataset.  
10.4.7  Updated to include the outcome of the interim 
safety analysis.  
 
 Updated since the 
planned interim safety 
analysis was completed 
in June 2019.  
13.1 Previously read:  For each subject who receives 
the study agent, the eCRF must be completed […]  
 Revised for clarity, as 
screen failure data is 
captured in the eCRF.  
 
 
Protocol ALK6021 -201                                                   V5.0 23SEP2019 
 
 
____________________________________________________________________________________________ 
CONFIDENTIAL/PROPRIETARY                                                                                                    Page 94 of 111  
 
 
Now reads : For each subject enrolled in the 
study, the eCRF must be completed […] 
13.[ADDRESS_210822] 
Operating Procedures 
related to Major and 
Minor Protocol 
Deviations.  
15.1 • Table modified to Word format  (previously 
embedded Excel image) for ease /tracking of 
revisions.  
• Visit 16 day interval was changed from “90 + 
3 Days” to “90 + 7 Days.” 
• Note  X4 updated as subjects should be 
randomized at least 5 days prior to treatment start to ensure study drug availability. 
• Note  b updated as treatment window is 6 days 
in the event of a “grace” day.  
• Note c updated with the following content, “The windows for Visits 16,17,18, and [ADDRESS_210823]’s first infusion during Treatment 
Period 2 (i.e., 85 ± 7 days). ” 
• Note e updated to include cross- reference to 
Section [IP_ADDRESS].[ADDRESS_210824] of labs was 
removed.  
• Note f updated to include cross -reference to 
Section [IP_ADDRESS].8.[ADDRESS_210825] of labs was 
removed.  
• Note g updated to include the following, 
“When using an i-STAT Handheld Blood Analyzer , the blood sample(s) may be 
obtained on the same day as the infusion for assessment prior to infusion start. ” In ad dition, 
cross -reference to Section  [IP_ADDRESS].[ADDRESS_210826] of labs was removed. 
• Note I was updated to include cross- reference 
to Sectio n [IP_ADDRESS].8.[ADDRESS_210827] of labs was 
removed.  
• Note j was updated by [CONTACT_179142] e follow -up 
assessments are conducted at consistent 
intervals post -treatment , 
to promote study feasibility , and for 
content standardization. 